[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcq226UjW-8Mn1_dI7xu05h5af0y9EPhboyrUDFlrTcM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University of Alberta",[4],800,false,190,61,394188,55,600,[14,17,20,22,25,27,30,33],{"name":15,"count":16},"Heart Failure",17,{"name":18,"count":19},"Type 1 Diabetes",13,{"name":21,"count":19},"Breast Cancer",{"name":23,"count":24},"Stroke",12,{"name":26,"count":24},"Obesity",{"name":28,"count":29},"Diabetes Mellitus, Type 2",11,{"name":31,"count":32},"Hypertension",10,{"name":34,"count":32},"Congenital Heart Disease",[36,41,46,51,55,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05738148","Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation","2026-01-13","Vasopressin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05823467","What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery","2026-06-01","TMP-SMX DS",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04444440","Antibiotic Prophylaxis for Bladder Botox","2026-06-30","Ciprofloxacin",{"nctId":52,"briefTitle":53,"date":49,"intervention":54},"NCT04520178","Effects of 5HTP on the Injured Human Spinal Cord","5-Hydroxytryptophan 100 MG",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06601465","COgnitioN With VERiciGuat Evaluation in Heart Failure","2026-07","Vericiguat",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04354129","Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.","2026-07-31","Cutaquig®",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06570473","Feasibility Trial for a Right Ventricular Failure Platform Trial","2026-08","Empagliflozin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04578652","Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance","2026-09","Metformin 850 mg oral tablet bid",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06053164","Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease","2026-09-01","Exertional Oxygen",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06474598","An Adaptive Design Study of MTX228","2026-10","MTX228",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,131,169,195,226,244,274,292,318,367,389,411,464,498,527,553,576,594,612,636,658,682,707,732,750,773,794,816,841,864,882,904,930,953,974,1000,1026,1044,1068,1137,1169,1191,1216,1234,1296,1321,1344,1366,1392,1410,1430,1455,1473,1502,1520,1547,1583,1623,1648,1673,1698,1722,1748,1766,1793,1811,1829,1855,1873,1899,1917,1935,1962,1987,2013,2038,2065,2089,2117,2135,2153,2171,2196,2220,2238,2264,2286,2310,2336,2354,2415,2450,2485,2520,2550,2576,2594,2616,2641,2666,2690,2708,2733,2751,2775,2799,2824,2850,2868,2892,2915,2940,2964,2990,3015,3040,3058,3081,3104,3127,3150,3172,3214,3257,3279,3313,3347,3371,3389,3415,3438,3465,3483,3508,3531,3556,3574,3592,3610,3628,3656,3674,3697,3724,3742,3766,3789,3811,3833,3858,3884,3909,3932,3957,3975,3993,4011,4035,4063,4081,4099,4124,4149,4174,4195,4218,4244,4262,4280,4305,4323,4347,4377,4395,4413,4431,4455,4480,4498,4524,4548,4566,4591,4614,4635,4659,4684,4706,4731,4749,4780,4798,4816,4840,4873,4891,4914,4937,4973,5011,5039,5076,5102,5137,5164,5186,5212,5234,5258,5279,5297,5320,5342,5360,5383,5408,5431,5449,5475,5493,5511,5535,5559,5577,5601,5623,5641,5664,5688,5706,5733,5759,5777,5800,5825,5843,5866,5884,5902,5924],{"intervention":50,"totalTrials":94,"cells":95},2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":117,"PHASE4":119,"NA":129},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":116,"soonestReadout":108},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":115},"NCT04791579","Antibiotic Prophylaxis for Neurogenic Bladder Botox","RECRUITING",[88],"2027-03-31","2027-08-31","2025-02-01",160,[113,114],"Neurogenic Bladder","Post-operative Urinary Tract Infections",[50],1,{"trials":118,"activeCount":98},[],{"trials":120,"activeCount":116,"soonestReadout":49},[121],{"nctId":47,"briefTitle":48,"status":106,"phases":122,"primaryCompletion":49,"completion":49,"start":123,"enrollment":124,"conditions":125,"interventions":128},[90],"2021-06-28",202,[126,127],"Idiopathic Overactive Bladder","Postoperative Urinary Tract Infection",[50],{"trials":130,"activeCount":98},[],{"intervention":132,"totalTrials":94,"cells":133},"Midodrine",{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":167},{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":116,"soonestReadout":161},[144,157],{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":156},"NCT04489589","Midodrine for the Early Liberation of Vasopressor Support in the ICU","COMPLETED",[90],"2022-07-31","2022-10-30","2021-03-22",20,[154,155],"Critical Illness","Shock",[132],{"nctId":158,"briefTitle":159,"status":106,"phases":160,"primaryCompletion":161,"completion":162,"start":151,"enrollment":163,"conditions":164,"interventions":166},"NCT05058612","Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)",[90],"2027-03","2028-02",870,[165],"Vasoplegia",[132],{"trials":168,"activeCount":98},[],{"intervention":170,"totalTrials":116,"cells":171},"Sotatercept",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":193},{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":98},[],{"trials":181,"activeCount":116,"soonestReadout":186},[182],{"nctId":183,"briefTitle":184,"status":106,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT07140484","Sotatercept in Pulmonary Arterial Hypertension",[90],"2029-01-01","2030-01-01","2025-10-06",27,[191],"Pulmonary Artery Hypertension",[170],{"trials":194,"activeCount":98},[],{"intervention":196,"totalTrials":116,"cells":197},"Envarsus Oral Product",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":224},{"trials":199,"activeCount":98},[],{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":116,"soonestReadout":212},[208],{"nctId":209,"briefTitle":210,"status":106,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":222},"NCT05242315","Extended-Release Tacrolimus Following Liver Transplantation",[90],"2026-12-15","2034-02-15","2022-05-15",94,[217,218,219,220,221],"Liver Transplant; Complications","Renal Insufficiency","Immunosuppressant Adverse Reaction","Metabolic Syndrome","Cardiovascular Diseases",[196,223],"Prograf",{"trials":225,"activeCount":98},[],{"intervention":223,"totalTrials":116,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":242},{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":116,"soonestReadout":212},[238],{"nctId":209,"briefTitle":210,"status":106,"phases":239,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":240,"interventions":241},[90],[217,218,219,220,221],[196,223],{"trials":243,"activeCount":98},[],{"intervention":245,"totalTrials":116,"cells":246},"Isoproterenol Hydrochloride",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":272},{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":116,"soonestReadout":261},[257],{"nctId":258,"briefTitle":259,"status":106,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT05997732","Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences",[90],"2027-12-01","2023-10-31",30,[265,266],"Vasoconstriction","Vasodilation",[268,245,269,270,271,268,245,270],"Phenylephrine Hydrochloride","Norepinephrine Bitartrate","Propranolol Hydrochloride","Phentolamine Mesylate",{"trials":273,"activeCount":98},[],{"intervention":269,"totalTrials":116,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":116,"soonestReadout":261},[286],{"nctId":258,"briefTitle":259,"status":106,"phases":287,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":288,"interventions":289},[90],[265,266],[268,245,269,270,271,268,245,270],{"trials":291,"activeCount":98},[],{"intervention":293,"totalTrials":116,"cells":294},"Tezepelumab",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":316},{"trials":296,"activeCount":98},[],{"trials":298,"activeCount":98},[],{"trials":300,"activeCount":98},[],{"trials":302,"activeCount":98},[],{"trials":304,"activeCount":116,"soonestReadout":310},[305],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT06705764","Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)","NOT_YET_RECRUITING",[90],"2026-11","2026-05-11",100,[314],"Severe Asthma",[293],{"trials":317,"activeCount":98},[],{"intervention":268,"totalTrials":319,"cells":320},4,{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":116,"soonestReadout":261},[331],{"nctId":258,"briefTitle":259,"status":106,"phases":332,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":333,"interventions":334},[90],[265,266],[268,245,269,270,271,268,245,270],{"trials":336,"activeCount":98},[337,348,357],{"nctId":338,"briefTitle":339,"status":147,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":346},"NCT04928183","The Impact of Carbon Monoxide and Altitude on Vascular Function",[91],"2021-08-01","2022-05-18","2021-06-10",19,[266,265],[347,268],"Sodium Nitroprusside",{"nctId":349,"briefTitle":350,"status":147,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":16,"conditions":354,"interventions":355},"NCT05525416","Sex Differences in Sympathetic Vascular Reactivity at High Altitude",[91],"2023-02-05","2022-07-28",[266,265],[347,268,268,356,270,271],"Norepinephrine",{"nctId":358,"briefTitle":359,"status":147,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":366},"NCT05001048","Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia.",[91],"2021-12-07","2022-09-09","2019-08-04",14,[266,265],[268],{"intervention":270,"totalTrials":94,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":383},{"trials":370,"activeCount":98},[],{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":116,"soonestReadout":261},[379],{"nctId":258,"briefTitle":259,"status":106,"phases":380,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":381,"interventions":382},[90],[265,266],[268,245,269,270,271,268,245,270],{"trials":384,"activeCount":98},[385],{"nctId":349,"briefTitle":350,"status":147,"phases":386,"primaryCompletion":352,"completion":352,"start":353,"enrollment":16,"conditions":387,"interventions":388},[91],[266,265],[347,268,268,356,270,271],{"intervention":271,"totalTrials":94,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":405},{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":116,"soonestReadout":261},[401],{"nctId":258,"briefTitle":259,"status":106,"phases":402,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":403,"interventions":404},[90],[265,266],[268,245,269,270,271,268,245,270],{"trials":406,"activeCount":98},[407],{"nctId":349,"briefTitle":350,"status":147,"phases":408,"primaryCompletion":352,"completion":352,"start":353,"enrollment":16,"conditions":409,"interventions":410},[91],[266,265],[347,268,268,356,270,271],{"intervention":412,"totalTrials":413,"cells":414},"Furosemide",3,{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":450,"NA":462},{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":116,"soonestReadout":427},[423,438],{"nctId":424,"briefTitle":425,"status":106,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":6,"conditions":429,"interventions":436},"NCT04706910","18F-DOPA II - PET Imaging Optimization",[89],"2027-12","2021-01-20",[430,431,432,433,434,435],"Congenital Hyperinsulinism","Neuroblastoma","Parkinson Disease","Lewy Body Disease","Neuroendocrine Tumors","Brain Tumor",[437,412],"18F-DOPA",{"nctId":439,"briefTitle":440,"status":441,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT00978354","Furosemide in Early Acute Kidney Injury","TERMINATED",[88,89],"2014-07","2009-09",72,[447],"Acute Renal Failure",[412,449],"Normal Saline",{"trials":451,"activeCount":98},[452],{"nctId":453,"briefTitle":454,"status":441,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":94,"conditions":458,"interventions":460},"NCT05915286","Diuretic Use in Hemodialysis Patients With Residual Renal Function",[90],"2025-02-21","2023-05-29",[459],"End Stage Renal Disease on Dialysis",[412,461],"Chlorthalidone",{"trials":463,"activeCount":98},[],{"intervention":465,"totalTrials":94,"cells":466},"Ketorolac",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":483,"PHASE4":494,"NA":496},{"trials":468,"activeCount":98},[],{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":98},[473],{"nctId":474,"briefTitle":475,"status":441,"phases":476,"primaryCompletion":477,"completion":478,"start":444,"enrollment":479,"conditions":480,"interventions":482},"NCT01498796","KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial",[88],"2013-05","2013-07",121,[481],"Recurrent Acute Tonsillitis",[465,449],{"trials":484,"activeCount":116,"soonestReadout":489},[485],{"nctId":486,"briefTitle":487,"status":106,"phases":488,"primaryCompletion":489,"completion":427,"start":490,"enrollment":263,"conditions":491,"interventions":493},"NCT06819956","Ketorolac at Lower Doses for Analgesic Pain Control in ICU: A Pilot Feasibility Study",[89],"2026-12","2025-06-23",[492],"Pain Management",[465],{"trials":495,"activeCount":98},[],{"trials":497,"activeCount":98},[],{"intervention":437,"totalTrials":94,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":523,"NA":525},{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":98},[],{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":116,"soonestReadout":427},[508,512],{"nctId":424,"briefTitle":425,"status":106,"phases":509,"primaryCompletion":427,"completion":427,"start":428,"enrollment":6,"conditions":510,"interventions":511},[89],[430,431,432,433,434,435],[437,412],{"nctId":513,"briefTitle":514,"status":147,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT03042416","18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety",[89],"2021-03-05","2021-06-02","2017-06-29",400,[430,431,434,432,521],"Brain Glioma",[437],{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[],{"intervention":528,"totalTrials":116,"cells":529},"18F-PSMA-1007",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":549,"NA":551},{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":116,"soonestReadout":542},[538],{"nctId":539,"briefTitle":540,"status":106,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT05520255","18F-PSMA-1007 PET\u002FCT in Prostate Cancer - Access Trial 2022 to 2028",[89],"2028-12","2029-12","2023-07-25",2800,[547],"Prostate Cancer",[528],{"trials":550,"activeCount":98},[],{"trials":552,"activeCount":98},[],{"intervention":54,"totalTrials":116,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":572,"NA":574},{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":116,"soonestReadout":49},[563],{"nctId":52,"briefTitle":53,"status":106,"phases":564,"primaryCompletion":49,"completion":565,"start":566,"enrollment":263,"conditions":567,"interventions":569},[88,89],"2026-12-30","2020-07-01",[568],"Spinal Cord Injuries",[54,570,571],"5-Hydroxytryptophan","Carbidopa",{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":98},[],{"intervention":570,"totalTrials":116,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":590,"NA":592},{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":116,"soonestReadout":49},[586],{"nctId":52,"briefTitle":53,"status":106,"phases":587,"primaryCompletion":49,"completion":565,"start":566,"enrollment":263,"conditions":588,"interventions":589},[88,89],[568],[54,570,571],{"trials":591,"activeCount":98},[],{"trials":593,"activeCount":98},[],{"intervention":571,"totalTrials":116,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":608,"NA":610},{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[],{"trials":603,"activeCount":116,"soonestReadout":49},[604],{"nctId":52,"briefTitle":53,"status":106,"phases":605,"primaryCompletion":49,"completion":565,"start":566,"enrollment":263,"conditions":606,"interventions":607},[88,89],[568],[54,570,571],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"intervention":613,"totalTrials":116,"cells":614},"Taurine",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":632,"NA":634},{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":116,"soonestReadout":162},[623],{"nctId":624,"briefTitle":625,"status":106,"phases":626,"primaryCompletion":162,"completion":542,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT06721949","Taurine Supplementation in Long COVID",[88,89],"2025-11-18",300,[630],"Long COVID",[613],{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"intervention":74,"totalTrials":116,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":654,"NA":656},{"trials":639,"activeCount":98},[],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":116,"soonestReadout":73},[646],{"nctId":71,"briefTitle":72,"status":106,"phases":647,"primaryCompletion":73,"completion":73,"start":648,"enrollment":649,"conditions":650,"interventions":653},[89],"2021-10-22",90,[651,652],"Obesity, Childhood","Insulin Resistance",[74],{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"intervention":659,"totalTrials":116,"cells":660},"Lyophilized fecal microbiota",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":116,"soonestReadout":108},[667],{"nctId":668,"briefTitle":669,"status":106,"phases":670,"primaryCompletion":108,"completion":108,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT05327790","LFMT vs Placebo in New Biologic Start for Ulcerative Colitis",[88],"2022-06-03",40,[674],"Ulcerative Colitis",[659],{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"intervention":683,"totalTrials":116,"cells":684},"Ferumoxytol",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":116,"soonestReadout":695},[691],{"nctId":692,"briefTitle":693,"status":106,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT06483061","Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy",[88],"2029-09-01","2025-05-01",50,[699],"Epilepsy, Temporal Lobe",[683],{"trials":702,"activeCount":98},[],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"intervention":708,"totalTrials":116,"cells":709},"aspirin + clopidogrel",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":116,"soonestReadout":565},[716],{"nctId":717,"briefTitle":718,"status":106,"phases":719,"primaryCompletion":565,"completion":108,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT06638151","Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and\u002For Intravenous Thrombolysis (CoPrime)",[88],"2025-09-02",200,[723],"Acute Ischemic Stroke",[708,725],"Aspirin",{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[],{"intervention":725,"totalTrials":116,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":116,"soonestReadout":565},[740],{"nctId":717,"briefTitle":718,"status":106,"phases":741,"primaryCompletion":565,"completion":108,"start":720,"enrollment":721,"conditions":742,"interventions":743},[88],[723],[708,725],{"trials":745,"activeCount":98},[],{"trials":747,"activeCount":98},[],{"trials":749,"activeCount":98},[],{"intervention":751,"totalTrials":116,"cells":752},"68Ga-HA-DOTATATE",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":116,"soonestReadout":109},[759],{"nctId":760,"briefTitle":761,"status":106,"phases":762,"primaryCompletion":109,"completion":763,"start":764,"enrollment":12,"conditions":765,"interventions":766},"NCT04888481","68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors",[88],"2028-08-31","2022-02-15",[434],[751],{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"intervention":79,"totalTrials":116,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":116,"soonestReadout":78},[781],{"nctId":76,"briefTitle":77,"status":106,"phases":782,"primaryCompletion":78,"completion":78,"start":783,"enrollment":784,"conditions":785,"interventions":787},[88],"2025-07-01",60,[786],"Fibrotic Interstitial Lung Disease",[79],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"intervention":59,"totalTrials":116,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":116,"soonestReadout":58},[802],{"nctId":56,"briefTitle":57,"status":106,"phases":803,"primaryCompletion":58,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":809},[88],"2027-05","2025-06-03",120,[15,808],"Cognitive Impairment",[59],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"intervention":817,"totalTrials":116,"cells":818},"Inhaled Nitric Oxide",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":116,"soonestReadout":261},[825],{"nctId":826,"briefTitle":827,"status":308,"phases":828,"primaryCompletion":261,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":834},"NCT04231760","The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD",[87,88],"2028-02-01","2026-12-01",80,[833],"Chronic Obstructive Pulmonary Disease",[817],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[],{"intervention":69,"totalTrials":116,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":844,"activeCount":98},[],{"trials":846,"activeCount":98},[],{"trials":848,"activeCount":116,"soonestReadout":68},[849],{"nctId":66,"briefTitle":67,"status":106,"phases":850,"primaryCompletion":68,"completion":489,"start":851,"enrollment":263,"conditions":852,"interventions":856},[88],"2025-07-15",[853,854,855],"Pulmonary Hypertension","Right Ventricular Dysfunction","Right Heart Failure",[69,857],"Ranolazine",{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"intervention":857,"totalTrials":116,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":116,"soonestReadout":68},[872],{"nctId":66,"briefTitle":67,"status":106,"phases":873,"primaryCompletion":68,"completion":489,"start":851,"enrollment":263,"conditions":874,"interventions":875},[88],[853,854,855],[69,857],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"intervention":883,"totalTrials":116,"cells":884},"Sildenafil Citrate",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":116,"soonestReadout":804},[891],{"nctId":892,"briefTitle":893,"status":106,"phases":894,"primaryCompletion":804,"completion":804,"start":895,"enrollment":111,"conditions":896,"interventions":897},"NCT05061368","Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD",[88],"2022-03-01",[833],[883],{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":98},[],{"intervention":905,"totalTrials":116,"cells":906},"Treatment with blinatumomab given subcutaneously.",{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":116,"soonestReadout":917},[913],{"nctId":914,"briefTitle":915,"status":308,"phases":916,"primaryCompletion":917,"completion":918,"start":919,"enrollment":831,"conditions":920,"interventions":923},"NCT07301424","Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",[88],"2027-12-31","2031-12","2026-07-01",[921,922],"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)","BCR-ABL Positive Acute Lymphoblastic Leukemia",[905],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"trials":929,"activeCount":98},[],{"intervention":931,"totalTrials":116,"cells":932},"Caffeine citrate",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":116,"soonestReadout":109},[939],{"nctId":940,"briefTitle":941,"status":308,"phases":942,"primaryCompletion":109,"completion":943,"start":78,"enrollment":152,"conditions":944,"interventions":946},"NCT06972108","CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)",[88],"2028-12-31",[945],"Meconium Aspiration Syndrome",[931],{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"intervention":84,"totalTrials":116,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":116,"soonestReadout":83},[961],{"nctId":81,"briefTitle":82,"status":106,"phases":962,"primaryCompletion":83,"completion":427,"start":963,"enrollment":964,"conditions":965,"interventions":967},[88],"2024-11-14",24,[966],"Type 1 Diabetes Mellitus",[84],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"intervention":975,"totalTrials":116,"cells":976},"autologous CD19-directed chimeric antigen receptor (CAR) T-cells",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":116,"soonestReadout":489},[983],{"nctId":984,"briefTitle":985,"status":106,"phases":986,"primaryCompletion":489,"completion":427,"start":987,"enrollment":988,"conditions":989,"interventions":993},"NCT03938987","Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed\u002FRefractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)",[87,88],"2021-03-03",63,[990,991,992],"Relapsed Non Hodgkin Lymphoma","Relapsed Adult ALL","Relapsed Pediatric ALL",[975],{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"intervention":1001,"totalTrials":116,"cells":1002},"Treprostinil Inhalation Solution 36 mcg",{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":116,"soonestReadout":1014},[1009],{"nctId":1010,"briefTitle":1011,"status":1012,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":152,"conditions":1016,"interventions":1018},"NCT06969573","Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD","ACTIVE_NOT_RECRUITING",[88],"2026-12-31","2025-06-05",[1017],"COPD (Chronic Obstructive Pulmonary Disease)",[1001,1019],"Treprostinil Inhalation Solution 78 mcg",{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"intervention":1019,"totalTrials":116,"cells":1027},{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":116,"soonestReadout":1014},[1034],{"nctId":1010,"briefTitle":1011,"status":1012,"phases":1035,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":152,"conditions":1036,"interventions":1037},[88],[1017],[1001,1019],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"intervention":1045,"totalTrials":116,"cells":1046},"Dobutamine",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1048,"activeCount":98},[],{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":116,"soonestReadout":1057},[1053],{"nctId":1054,"briefTitle":1055,"status":308,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":672,"conditions":1059,"interventions":1061},"NCT07406477","The PROTECT-HIE Pilot Trial",[88],"2029-04-30","2026-05-01",[1060],"Hypoxic-ischemic Encephalopathy (HIE)",[1045],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"intervention":1069,"totalTrials":319,"cells":1070},"Metformin",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1101,"PHASE3":1122,"PHASE4":1133,"NA":1135},{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":116,"soonestReadout":565},[1075,1087],{"nctId":1076,"briefTitle":1077,"status":147,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1085},"NCT04116203","Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)",[87],"2020-11-12","2016-06-30",52,[1083,1084],"Polycystic Ovary Syndrome","Lipid Metabolism Disorders",[1069,1086],"Fish Oil and Metformin",{"nctId":1088,"briefTitle":1089,"status":106,"phases":1090,"primaryCompletion":565,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1100},"NCT06424860","Fish Oil, Metformin and Heart Health in PCOS",[87],"2027-12-30","2025-11-01",146,[1095,1096,1097,1098,1099],"PCOS","Cardiovascular Disease","Atherosclerotic Cardiovascular Disease","Atherosclerotic Plaque","Cardiac Hypertrophy",[1069,1086],{"trials":1102,"activeCount":98},[1103],{"nctId":1104,"briefTitle":1105,"status":147,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1121},"NCT03862950","A Trial of Metformin in Individuals With Fragile X Syndrome (Met)",[88],"2025-12-16","2019-05-24",125,[1111,1112,1113,1114,1115,1116,1117,1118,1119,1120],"Fragile X Syndrome","Fragile X Mental Retardation Syndrome","Mental Retardation, X-Linked","Genetic Diseases, X-Linked","Trinucleotide Repeat Expansion","Fra(X) Syndrome","Intellectual Disability","FXS","Neurobehavioral Manifestations","Sex Chromosome Disorders",[1069],{"trials":1123,"activeCount":98},[1124],{"nctId":1125,"briefTitle":1126,"status":441,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":312,"conditions":1130,"interventions":1132},"NCT00325910","Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study",[89],"2007-05","2006-05",[28,1131],"Heart Failure, Congestive",[1069],{"trials":1134,"activeCount":98},[],{"trials":1136,"activeCount":98},[],{"intervention":40,"totalTrials":94,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1152,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":116,"soonestReadout":39},[1143],{"nctId":37,"briefTitle":38,"status":1012,"phases":1144,"primaryCompletion":39,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1150},[87],"2028-02-28","2023-11-27",8,[1149],"Cardiac Arrest Neonatal",[40,1151],"Epinephrine",{"trials":1153,"activeCount":98},[1154],{"nctId":1155,"briefTitle":1156,"status":441,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":413,"conditions":1160,"interventions":1161},"NCT01370096","Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension",[88],"2016-09","2012-02",[853],[40,1162],"Vasopressin infusion and epoprostenol inhalation",{"trials":1164,"activeCount":98},[],{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"intervention":1086,"totalTrials":94,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":116,"soonestReadout":565},[1175,1179],{"nctId":1076,"briefTitle":1077,"status":147,"phases":1176,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1177,"interventions":1178},[87],[1083,1084],[1069,1086],{"nctId":1088,"briefTitle":1089,"status":106,"phases":1180,"primaryCompletion":565,"completion":1091,"start":1092,"enrollment":1093,"conditions":1181,"interventions":1182},[87],[1095,1096,1097,1098,1099],[1069,1086],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"intervention":1192,"totalTrials":116,"cells":1193},"AVIHepC1",{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1195,"activeCount":98},[],{"trials":1197,"activeCount":116,"soonestReadout":1202},[1198],{"nctId":1199,"briefTitle":1200,"status":308,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":189,"conditions":1205,"interventions":1207},"NCT07237282","A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)",[87],"2027-01-01","2027-07-01","2026-08-01",[1206],"Hepatitis C",[1192,449],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[],{"intervention":1151,"totalTrials":116,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":116,"soonestReadout":39},[1222],{"nctId":37,"briefTitle":38,"status":1012,"phases":1223,"primaryCompletion":39,"completion":1145,"start":1146,"enrollment":1147,"conditions":1224,"interventions":1225},[87],[1149],[40,1151],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[],{"intervention":449,"totalTrials":1235,"cells":1236},6,{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1245,"PHASE3":1263,"PHASE4":1280,"NA":1282},{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":116,"soonestReadout":1202},[1241],{"nctId":1199,"briefTitle":1200,"status":308,"phases":1242,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":189,"conditions":1243,"interventions":1244},[87],[1206],[1192,449],{"trials":1246,"activeCount":98},[1247,1251],{"nctId":474,"briefTitle":475,"status":441,"phases":1248,"primaryCompletion":477,"completion":478,"start":444,"enrollment":479,"conditions":1249,"interventions":1250},[88],[481],[465,449],{"nctId":1252,"briefTitle":1253,"status":147,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1261},"NCT01073787","Intravenous Fluid for Pediatric Migraine in the Emergency Department",[87,88],"2012-11","2010-07",46,[1259,1260],"Migraine","Headache",[1262],"Normal saline",{"trials":1264,"activeCount":98},[1265,1276],{"nctId":1266,"briefTitle":1267,"status":147,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":189,"conditions":1271,"interventions":1274},"NCT03533452","The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane",[88,89],"2022-01-01","2019-05-01",[1272,1273],"Rotator Cuff Injury","Anesthesia; Functional",[1275,1262],"Ropivacaine",{"nctId":439,"briefTitle":440,"status":441,"phases":1277,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":1278,"interventions":1279},[88,89],[447],[412,449],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[1284],{"nctId":1285,"briefTitle":1286,"status":147,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1294},"NCT01111669","Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery",[91],"2011-12","2009-08",28,[1292,1293],"Chronic Rhinosinusitis With Polyposis","Chronic Hyperplastic Sinusitis",[1295,449],"Tranexamic Acid",{"intervention":1297,"totalTrials":116,"cells":1298},"Dexmedetomidine",{"EARLY_PHASE1":1299,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1300,"activeCount":116,"soonestReadout":1305},[1301],{"nctId":1302,"briefTitle":1303,"status":308,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1204,"enrollment":697,"conditions":1306,"interventions":1310},"NCT06824077","Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle",[86],"2027-03-01",[1307,1308,1309],"Sleep","Delirium","ICU Hospitalization",[1297],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"intervention":1322,"totalTrials":116,"cells":1323},"Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408",{"EARLY_PHASE1":1324,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1325,"activeCount":116,"soonestReadout":1014},[1326],{"nctId":1327,"briefTitle":1328,"status":106,"phases":1329,"primaryCompletion":1014,"completion":1014,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1333},"NCT05467215","Can Brief Exposure to Hyperoxia Improve Function After Chronic Spinal Cord Injury?",[86],"2022-07-11",25,[568],[1322],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":98},[],{"intervention":64,"totalTrials":116,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":116,"soonestReadout":63},[1358],{"nctId":61,"briefTitle":62,"status":1012,"phases":1359,"primaryCompletion":63,"completion":63,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1365},[],"2023-04-01",36,[1363,1364],"Primary Immune Deficiency Disorder","Secondary Immune Deficiency",[64],{"intervention":1367,"totalTrials":116,"cells":1368},"60% Oxygen Group - Infants will start in 60% oxygen",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":116,"soonestReadout":1385},[1381],{"nctId":1382,"briefTitle":1383,"status":308,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":919,"enrollment":1387,"conditions":1388,"interventions":1390},"NCT07315594","Initial Oxygen Concentration at Birth in Late-Preterm Infants",[91],"2029-06-30","2029-12-31",1520,[1389],"Preterm Birth",[1367,1391],"30% Oxygen Group - Infants will start in 30% oxygen",{"intervention":1391,"totalTrials":116,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1395,"activeCount":98},[],{"trials":1397,"activeCount":98},[],{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[],{"trials":1405,"activeCount":116,"soonestReadout":1385},[1406],{"nctId":1382,"briefTitle":1383,"status":308,"phases":1407,"primaryCompletion":1385,"completion":1386,"start":919,"enrollment":1387,"conditions":1408,"interventions":1409},[91],[1389],[1367,1391],{"intervention":45,"totalTrials":116,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[],{"trials":1421,"activeCount":98},[],{"trials":1423,"activeCount":116,"soonestReadout":44},[1424],{"nctId":42,"briefTitle":43,"status":106,"phases":1425,"primaryCompletion":44,"completion":1014,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1429},[91],"2023-06-26",105,[21],[45],{"intervention":1431,"totalTrials":116,"cells":1432},"Immune Globulin Intravenous (Human), 10%",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":116,"soonestReadout":1449},[1445],{"nctId":1446,"briefTitle":1447,"status":106,"phases":1448,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":263,"conditions":1451,"interventions":1453},"NCT06989541","Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy",[],"2027-05-01","2025-06-01",[1452],"Hypogammaglobulinemia, Acquired",[1431,1454],"Immune Globulin Subcutaneous (Human), 20% Solution",{"intervention":1454,"totalTrials":116,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1458,"activeCount":98},[],{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":116,"soonestReadout":1449},[1469],{"nctId":1446,"briefTitle":1447,"status":106,"phases":1470,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":263,"conditions":1471,"interventions":1472},[],[1452],[1431,1454],{"intervention":1474,"totalTrials":116,"cells":1475},"30% oxygen group",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":116,"soonestReadout":1492},[1488],{"nctId":1489,"briefTitle":1490,"status":106,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1500},"NCT03825835","30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants",[91],"2027-09-30","2029-12-30","2022-06-27",1200,[1497,1498,1499],"Premature Infant","Respiratory Distress Syndrome in Premature Infant","Neurodevelopmental Outcome",[1474,1501],"60% oxygen group",{"intervention":1501,"totalTrials":116,"cells":1503},{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1512,"NA":1514},{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":116,"soonestReadout":1492},[1516],{"nctId":1489,"briefTitle":1490,"status":106,"phases":1517,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":1518,"interventions":1519},[91],[1497,1498,1499],[1474,1501],{"intervention":1521,"totalTrials":116,"cells":1522},"Soothing Beta Cream",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[],{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":116,"soonestReadout":1449},[1535],{"nctId":1536,"briefTitle":1537,"status":308,"phases":1538,"primaryCompletion":1449,"completion":1539,"start":1058,"enrollment":784,"conditions":1540,"interventions":1546},"NCT07524439","Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent",[91],"2028-11-30",[1541,1542,1543,1544,1545],"Fecal Incontinence","Urinary Incontinence","Diaper Rash","Irritant Contact Dermatitis Caused by Faeces","Irritant Contact Dermatitis",[1521],{"intervention":1548,"totalTrials":94,"cells":1549},"adalimumab",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1565,"PHASE4":1567,"NA":1581},{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[1556],{"nctId":1557,"briefTitle":1558,"status":147,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":152,"conditions":1562,"interventions":1564},"NCT00686439","Adalimumab for Inflammatory Osteoarthritis",[87,88],"2010-11","2008-06",[1563],"Osteoarthritis",[1548,1548],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[1569],{"nctId":1570,"briefTitle":1571,"status":1572,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":98,"conditions":1576,"interventions":1579},"NCT00972218","Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease","WITHDRAWN",[90],"2010-01","2009-07",[1577,1578],"Spondyloarthritis","Crohn's Disease",[1580],"Adalimumab",{"trials":1582,"activeCount":98},[],{"intervention":1584,"totalTrials":94,"cells":1585},"warfarin",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1621},{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[1590],{"nctId":1591,"briefTitle":1592,"status":147,"phases":1593,"primaryCompletion":1594,"completion":1594,"start":1256,"enrollment":1595,"conditions":1596,"interventions":1598},"NCT01124058","Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial",[87],"2012-08",39,[1597],"Anticoagulation",[1584,1599],"Warfarin",{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":98},[1606],{"nctId":1607,"briefTitle":1608,"status":147,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1620},"NCT02376803","The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The \"INRange\" RCT",[90],"2016-09-30","2018-04-27","2015-02",217,[1615,1616,1617,1618,1619],"Atrial Fibrillation","Thrombus Due to Heart Valve Prosthesis","Deep Venous Thrombosis","Thromboembolism","DVT",[1599],{"trials":1622,"activeCount":98},[],{"intervention":1624,"totalTrials":116,"cells":1625},"Zostavax",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1646},{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[1636],{"nctId":1637,"briefTitle":1638,"status":147,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":319,"conditions":1643,"interventions":1645},"NCT00940940","Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation",[90],"2013-08-26","2013-09-23","2009-10",[1644],"Kidney Transplant",[1624],{"trials":1647,"activeCount":98},[],{"intervention":1649,"totalTrials":116,"cells":1650},"Liposomal Lidocaine",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1671},{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[1661],{"nctId":1662,"briefTitle":1663,"status":147,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1670},"NCT01542125","The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting",[90],"2011-02","2008-09",281,[1669],"Pain",[1649],{"trials":1672,"activeCount":98},[],{"intervention":1674,"totalTrials":116,"cells":1675},"Anticoagulants",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1696},{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[1686],{"nctId":1687,"briefTitle":1688,"status":147,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1695},"NCT03126214","Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing",[90],"2022-07-01","2023-12-01","2018-02-01",79,[1615,23],[1674],{"trials":1697,"activeCount":98},[],{"intervention":1699,"totalTrials":116,"cells":1700},"inhaled corticosteroid",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1720},{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[1711],{"nctId":1712,"briefTitle":1713,"status":441,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":1235,"conditions":1717,"interventions":1719},"NCT00395239","Asthma\u002FSteroid Withdrawal Study",[90],"2015-10","2006-10",[1718],"Asthma",[1699],{"trials":1721,"activeCount":98},[],{"intervention":1723,"totalTrials":116,"cells":1724},"Antihypertensive agents and lipid lowering therapy",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1746},{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[1735],{"nctId":1736,"briefTitle":1737,"status":147,"phases":1738,"primaryCompletion":477,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1745},"NCT00931788","Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack",[90],"2013-11","2009-01",279,[1743,1744],"Ischemic Stroke","Transient Ischemic Attacks",[1723],{"trials":1747,"activeCount":98},[],{"intervention":461,"totalTrials":116,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1764},{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[1760],{"nctId":453,"briefTitle":454,"status":441,"phases":1761,"primaryCompletion":456,"completion":456,"start":457,"enrollment":94,"conditions":1762,"interventions":1763},[90],[459],[412,461],{"trials":1765,"activeCount":98},[],{"intervention":1767,"totalTrials":116,"cells":1768},"Standard Triple",{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1791},{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[1779],{"nctId":1780,"briefTitle":1781,"status":147,"phases":1782,"primaryCompletion":1783,"completion":1783,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1788},"NCT01967329","CANHelp Working Group Treatment Trials",[90],"2019-05","2008-11",338,[1787],"Helicobacter Pylori Infection",[1767,1789,1790],"Sequential","Quadruple",{"trials":1792,"activeCount":98},[],{"intervention":1789,"totalTrials":116,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1803,"NA":1809},{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[1805],{"nctId":1780,"briefTitle":1781,"status":147,"phases":1806,"primaryCompletion":1783,"completion":1783,"start":1784,"enrollment":1785,"conditions":1807,"interventions":1808},[90],[1787],[1767,1789,1790],{"trials":1810,"activeCount":98},[],{"intervention":1790,"totalTrials":116,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1827},{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[1823],{"nctId":1780,"briefTitle":1781,"status":147,"phases":1824,"primaryCompletion":1783,"completion":1783,"start":1784,"enrollment":1785,"conditions":1825,"interventions":1826},[90],[1787],[1767,1789,1790],{"trials":1828,"activeCount":98},[],{"intervention":1830,"totalTrials":116,"cells":1831},"Pearlium\u002FEffectiCal",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1853},{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[1842],{"nctId":1843,"briefTitle":1844,"status":147,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT04609189","Pearlium®\u002FEffecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss",[90],"2014-05-02","2012-07-12",97,[1850],"Osteoporosis, Postmenopausal",[1830,1852],"Calcium carbonate\u002Fvitamin D3",{"trials":1854,"activeCount":98},[],{"intervention":1852,"totalTrials":116,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1871},{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[1867],{"nctId":1843,"briefTitle":1844,"status":147,"phases":1868,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1869,"interventions":1870},[90],[1850],[1830,1852],{"trials":1872,"activeCount":98},[],{"intervention":1874,"totalTrials":116,"cells":1875},"Clonazepam mixed with Mucolox®",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1897},{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[1886],{"nctId":1887,"briefTitle":1888,"status":1572,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":98,"conditions":1892,"interventions":1894},"NCT02690844","Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome",[90],"2016-05","2016-04",[1893],"Burning Mouth Syndrome",[1874,1895,1896],"Mucolox® alone","Clonazepam",{"trials":1898,"activeCount":98},[],{"intervention":1895,"totalTrials":116,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1907,"PHASE4":1909,"NA":1915},{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[1911],{"nctId":1887,"briefTitle":1888,"status":1572,"phases":1912,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":98,"conditions":1913,"interventions":1914},[90],[1893],[1874,1895,1896],{"trials":1916,"activeCount":98},[],{"intervention":1896,"totalTrials":116,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1933},{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[],{"trials":1928,"activeCount":98},[1929],{"nctId":1887,"briefTitle":1888,"status":1572,"phases":1930,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":98,"conditions":1931,"interventions":1932},[90],[1893],[1874,1895,1896],{"trials":1934,"activeCount":98},[],{"intervention":1936,"totalTrials":116,"cells":1937},"Depo-Medrol Injectable Product",{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1960},{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[1948],{"nctId":1949,"briefTitle":1950,"status":147,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":9,"conditions":1955,"interventions":1958},"NCT04177433","The Use of Intra-articular Corticosteroid Injection to Treat Osteoarthritis of the Carpometacarpal Joint",[90],"2025-09-29","2025-12-31","2020-12-02",[1956,1957],"Osteoarthritis of the Carpometacarpal Joint","Thumb Osteoarthritis",[1936,1959],"Saline",{"trials":1961,"activeCount":98},[],{"intervention":1963,"totalTrials":116,"cells":1964},"Lidocaine 2% Polyampoule",{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1971,"PHASE4":1973,"NA":1985},{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"trials":1974,"activeCount":98},[1975],{"nctId":1976,"briefTitle":1977,"status":147,"phases":1978,"primaryCompletion":1979,"completion":39,"start":1980,"enrollment":1981,"conditions":1982,"interventions":1984},"NCT05854082","Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia",[90],"2025-07-10","2023-08-24",56,[1983],"Reading Disorders",[1963],{"trials":1986,"activeCount":98},[],{"intervention":1988,"totalTrials":116,"cells":1989},"Ketorolac Tromethamine",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2011},{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[2000],{"nctId":2001,"briefTitle":2002,"status":147,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":1159,"enrollment":1981,"conditions":2005,"interventions":2009},"NCT01596166","Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department",[90],"2014-04",[2006,2007,2008],"Probable Migraine","Migraine With Aura","Migraine Without Aura",[1988,2010],"Metoclopramide",{"trials":2012,"activeCount":98},[],{"intervention":2014,"totalTrials":116,"cells":2015},"unfractionated heparin",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2036},{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[2026],{"nctId":2027,"briefTitle":2028,"status":147,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT01634438","Heparin Dose for Radial Angiography",[90],"2010-12","2008-07",49,[2034],"Coronary Angiograph",[2014],{"trials":2037,"activeCount":98},[],{"intervention":2039,"totalTrials":116,"cells":2040},"Optimizing therapeutic treatments",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2063},{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[2051],{"nctId":2052,"briefTitle":2053,"status":147,"phases":2054,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2062},"NCT00351676","Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment",[90],"2007-07","2006-02",452,[1131,2059,2060,28,2061],"Pulmonary Disease, Chronic Obstructive","Pneumonia","Coronary Arteriosclerosis",[2039],{"trials":2064,"activeCount":98},[],{"intervention":2066,"totalTrials":116,"cells":2067},"anti-thrombotic treatment using Aspirin",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2087},{"trials":2069,"activeCount":98},[],{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[2078],{"nctId":2079,"briefTitle":2080,"status":1572,"phases":2081,"primaryCompletion":2082,"completion":2083,"start":443,"enrollment":98,"conditions":2084,"interventions":2086},"NCT02144831","The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack",[90],"2018-06","2018-10",[1744,2085],"Minor Stroke",[2066],{"trials":2088,"activeCount":98},[],{"intervention":2090,"totalTrials":116,"cells":2091},"B\u002FF\u002FTAF",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2115},{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"trials":2097,"activeCount":98},[],{"trials":2099,"activeCount":98},[],{"trials":2101,"activeCount":98},[2102],{"nctId":2103,"briefTitle":2104,"status":441,"phases":2105,"primaryCompletion":2106,"completion":2107,"start":2108,"enrollment":1290,"conditions":2109,"interventions":2111},"NCT03532425","B\u002FF\u002FTAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults",[90],"2020-08-03","2020-09-03","2018-10-29",[2110],"HIV-1-infection",[2090,2112,2113,2114],"Atripla","B\u002FF\u002FTAF Placebo","Atripla Placebo",{"trials":2116,"activeCount":98},[],{"intervention":2112,"totalTrials":116,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2125,"PHASE4":2127,"NA":2133},{"trials":2120,"activeCount":98},[],{"trials":2122,"activeCount":98},[],{"trials":2124,"activeCount":98},[],{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":98},[2129],{"nctId":2103,"briefTitle":2104,"status":441,"phases":2130,"primaryCompletion":2106,"completion":2107,"start":2108,"enrollment":1290,"conditions":2131,"interventions":2132},[90],[2110],[2090,2112,2113,2114],{"trials":2134,"activeCount":98},[],{"intervention":2113,"totalTrials":116,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2145,"NA":2151},{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[2147],{"nctId":2103,"briefTitle":2104,"status":441,"phases":2148,"primaryCompletion":2106,"completion":2107,"start":2108,"enrollment":1290,"conditions":2149,"interventions":2150},[90],[2110],[2090,2112,2113,2114],{"trials":2152,"activeCount":98},[],{"intervention":2114,"totalTrials":116,"cells":2154},{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2163,"NA":2169},{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[2165],{"nctId":2103,"briefTitle":2104,"status":441,"phases":2166,"primaryCompletion":2106,"completion":2107,"start":2108,"enrollment":1290,"conditions":2167,"interventions":2168},[90],[2110],[2090,2112,2113,2114],{"trials":2170,"activeCount":98},[],{"intervention":2172,"totalTrials":116,"cells":2173},"Tisseel",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2194},{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[2184],{"nctId":2185,"briefTitle":2186,"status":1572,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":98,"conditions":2191,"interventions":2193},"NCT02953145","The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery",[90],"2020-09-01","2020-12-01","2019-09-01",[2192],"Cleft Palate",[2172],{"trials":2195,"activeCount":98},[],{"intervention":2197,"totalTrials":116,"cells":2198},"tiotropium",{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2218},{"trials":2200,"activeCount":98},[],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[2209],{"nctId":2210,"briefTitle":2211,"status":1572,"phases":2212,"primaryCompletion":2213,"completion":2213,"start":2214,"enrollment":98,"conditions":2215,"interventions":2216},"NCT00546234","Tiotropium for Smoking Asthmatics Study",[90],"2014-01","2007-11",[1718],[2197,2217],"long acting beta agonist",{"trials":2219,"activeCount":98},[],{"intervention":2217,"totalTrials":116,"cells":2221},{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2230,"NA":2236},{"trials":2223,"activeCount":98},[],{"trials":2225,"activeCount":98},[],{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[2232],{"nctId":2210,"briefTitle":2211,"status":1572,"phases":2233,"primaryCompletion":2213,"completion":2213,"start":2214,"enrollment":98,"conditions":2234,"interventions":2235},[90],[1718],[2197,2217],{"trials":2237,"activeCount":98},[],{"intervention":2239,"totalTrials":116,"cells":2240},"Nasonex",{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2247,"PHASE4":2249,"NA":2262},{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[2251],{"nctId":2252,"briefTitle":2253,"status":1572,"phases":2254,"primaryCompletion":2255,"completion":2256,"start":477,"enrollment":98,"conditions":2257,"interventions":2261},"NCT01861145","Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea",[90],"2015-12","2016-06",[2258,2259,2260],"Enuresis","Obstructive Sleep Apnea","Sleep Disordered Breathing",[2239],{"trials":2263,"activeCount":98},[],{"intervention":2265,"totalTrials":116,"cells":2266},"risedronate",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2284},{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[],{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[2277],{"nctId":2278,"briefTitle":2279,"status":147,"phases":2280,"conditions":2281,"interventions":2283},"NCT01215890","Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease",[90],[1578,2282],"Low Bone Mineral Density",[2265],{"trials":2285,"activeCount":98},[],{"intervention":2287,"totalTrials":116,"cells":2288},"Rectal indomethacin 100mg one time before or after ERCP",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2308},{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[2299],{"nctId":2300,"briefTitle":2301,"status":147,"phases":2302,"primaryCompletion":2303,"completion":2303,"start":2004,"enrollment":2304,"conditions":2305,"interventions":2307},"NCT02111707","Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)",[90],"2017-09",534,[2306],"Acute Pancreatitis",[2287],{"trials":2309,"activeCount":98},[],{"intervention":2311,"totalTrials":116,"cells":2312},"Edoxaban 60 MG",{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2319,"PHASE4":2321,"NA":2334},{"trials":2314,"activeCount":98},[],{"trials":2316,"activeCount":98},[],{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[2323],{"nctId":2324,"briefTitle":2325,"status":147,"phases":2326,"primaryCompletion":2327,"completion":2327,"start":2328,"enrollment":2329,"conditions":2330,"interventions":2332},"NCT03494530","Lixiana Acute Stroke Evaluation Registry",[90],"2021-12-01","2018-06-01",70,[1743,1615,2331],"Hemorrhagic Transformation Stroke",[2311,2333],"Edoxaban 30 mg",{"trials":2335,"activeCount":98},[],{"intervention":2333,"totalTrials":116,"cells":2337},{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2344,"PHASE4":2346,"NA":2352},{"trials":2339,"activeCount":98},[],{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[2348],{"nctId":2324,"briefTitle":2325,"status":147,"phases":2349,"primaryCompletion":2327,"completion":2327,"start":2328,"enrollment":2329,"conditions":2350,"interventions":2351},[90],[1743,1615,2331],[2311,2333],{"trials":2353,"activeCount":98},[],{"intervention":2355,"totalTrials":2356,"cells":2357},"Fecal Microbiota Transplant",5,{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2398,"PHASE4":2411,"NA":2413},{"trials":2359,"activeCount":98},[],{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[2364,2371,2377,2388],{"nctId":2365,"briefTitle":2366,"status":147,"phases":2367,"primaryCompletion":2368,"completion":2368,"start":443,"enrollment":413,"conditions":2369,"interventions":2370},"NCT02199561","Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease",[87,88],"2016-12",[1578],[2355],{"nctId":2372,"briefTitle":2373,"status":147,"phases":2374,"primaryCompletion":2368,"completion":2368,"start":443,"enrollment":413,"conditions":2375,"interventions":2376},"NCT02227342","Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis",[87,88],[674],[2355],{"nctId":2378,"briefTitle":2379,"status":147,"phases":2380,"primaryCompletion":2381,"completion":2382,"start":2383,"enrollment":2384,"conditions":2385,"interventions":2387},"NCT03078803","Fecal Transplant for Crohn's Disease",[88],"2021-06-21","2022-08-29","2017-03-28",38,[2386],"Crohn Disease",[2355],{"nctId":2389,"briefTitle":2390,"status":147,"phases":2391,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":319,"conditions":2395,"interventions":2397},"NCT02255617","Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study",[87,88],"2019-07-25","2019-09-23","2014-07-23",[2396],"Hepatic Encephalopathy",[2355],{"trials":2399,"activeCount":98},[2400],{"nctId":2401,"briefTitle":2402,"status":147,"phases":2403,"primaryCompletion":2404,"completion":2405,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2410},"NCT02254811","FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff",[88,89],"2016-12-12","2017-09-13","2014-09-18",116,[2409],"Enterocolitis Clostridium Difficile Recurrent",[2355],{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"intervention":2416,"totalTrials":94,"cells":2417},"Tenecteplase",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2433,"PHASE4":2446,"NA":2448},{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[2424],{"nctId":2425,"briefTitle":2426,"status":147,"phases":2427,"primaryCompletion":2428,"completion":2428,"start":1642,"enrollment":152,"conditions":2429,"interventions":2432},"NCT02101606","Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke",[88],"2017-11",[2430,2431,23],"Cerebral Infarction","Brain Ischemia",[2416],{"trials":2434,"activeCount":98},[2435],{"nctId":2436,"briefTitle":2437,"status":147,"phases":2438,"start":2439,"enrollment":628,"conditions":2440,"interventions":2442},"NCT00121446","Which Therapy for Acute Heart Attacks? (The WEST Study)",[88,89],"2003-07",[2441],"Myocardial Infarction",[2443,2444,2445],"tenecteplase","enoxaparin","clopidogrel",{"trials":2447,"activeCount":98},[],{"trials":2449,"activeCount":98},[],{"intervention":2451,"totalTrials":94,"cells":2452},"Dextrose 5",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2459,"PHASE4":2481,"NA":2483},{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[2461,2472],{"nctId":2462,"briefTitle":2463,"status":1572,"phases":2464,"primaryCompletion":1269,"completion":1269,"start":2465,"enrollment":98,"conditions":2466,"interventions":2470},"NCT04021264","The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery",[88,89],"2019-08-01",[2467,2468,2469,1273],"Bowel Disease","Liver Diseases","Pancreas Disease",[2471,2451],"Ropivacaine-Sufentanil",{"nctId":2473,"briefTitle":2474,"status":1572,"phases":2475,"primaryCompletion":2476,"completion":2476,"start":2465,"enrollment":98,"conditions":2477,"interventions":2480},"NCT04022057","The Impact of a Preoperative Nerve Block in Foot and Ankle Surgery on the Consumption of Sevoflurane",[88,89],"2020-03-15",[2478,1273,2479],"Ankle Arthropathy","Ankle Arthritis",[1275,2451],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"intervention":2486,"totalTrials":94,"cells":2487},"Sirolimus",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2505,"PHASE4":2516,"NA":2518},{"trials":2489,"activeCount":98},[],{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[2494],{"nctId":2495,"briefTitle":2496,"status":147,"phases":2497,"primaryCompletion":2498,"completion":2498,"start":1890,"enrollment":319,"conditions":2499,"interventions":2500},"NCT02821026","Omental Islet Transplant",[87,88],"2019-11-13",[18],[2501,2502,2503,2504,2486],"Anti-Thymocyte Globulin","Mycophenolate mofetil","Tacrolimus","Etanercept",{"trials":2506,"activeCount":98},[2507],{"nctId":2508,"briefTitle":2509,"status":147,"phases":2510,"primaryCompletion":2511,"completion":2511,"start":2512,"enrollment":2329,"conditions":2513,"interventions":2515},"NCT00328770","De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma",[88,89],"2006-03","1996-12",[2514],"Liver Carcinoma",[2486],{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[],{"intervention":2444,"totalTrials":94,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2540,"PHASE4":2546,"NA":2548},{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[2528],{"nctId":2529,"briefTitle":2530,"status":441,"phases":2531,"primaryCompletion":2532,"completion":2533,"start":1716,"enrollment":2534,"conditions":2535,"interventions":2538},"NCT00769873","Anticoagulation Post Laparoscopic Splenectomy",[88],"2009-04","2009-05",35,[2536,2537],"Portal Vein Thrombosis","Splenic Vein Thrombosis",[2539],"Enoxaparin",{"trials":2541,"activeCount":98},[2542],{"nctId":2436,"briefTitle":2437,"status":147,"phases":2543,"start":2439,"enrollment":628,"conditions":2544,"interventions":2545},[88,89],[2441],[2443,2444,2445],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"intervention":2551,"totalTrials":116,"cells":2552},"Albumin (Human) 5%, USP",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2572,"NA":2574},{"trials":2554,"activeCount":98},[],{"trials":2556,"activeCount":98},[],{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[2561],{"nctId":2562,"briefTitle":2563,"status":1572,"phases":2564,"primaryCompletion":2565,"completion":2566,"start":2567,"enrollment":98,"conditions":2568,"interventions":2570},"NCT03365414","A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS",[89],"2023-10","2024-03","2022-01",[2569],"Postural Orthostatic Tachycardia Syndrome",[2551,2571],"Normal Saline 0.9% Infusion Solution Bag",{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[],{"intervention":2571,"totalTrials":116,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2584,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":98},[],{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[2586],{"nctId":2562,"briefTitle":2563,"status":1572,"phases":2587,"primaryCompletion":2565,"completion":2566,"start":2567,"enrollment":98,"conditions":2588,"interventions":2589},[89],[2569],[2551,2571],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[],{"intervention":2595,"totalTrials":116,"cells":2596},"Progesterone Effervescent Vaginal",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2612,"NA":2614},{"trials":2598,"activeCount":98},[],{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[2605],{"nctId":2606,"briefTitle":2607,"status":147,"phases":2608,"primaryCompletion":1610,"completion":1610,"start":443,"enrollment":628,"conditions":2609,"interventions":2611},"NCT01941875","Luteal Phase Progesterone in IUI and Gonadotropin Cycles",[89],[2610],"Infertility",[2595],{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[],{"intervention":2617,"totalTrials":116,"cells":2618},"Human papillomavirus quadrivalent vaccine",{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2623,"PHASE3":2625,"PHASE4":2637,"NA":2639},{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[2627],{"nctId":2628,"briefTitle":2629,"status":147,"phases":2630,"primaryCompletion":2631,"completion":2632,"start":2633,"enrollment":697,"conditions":2634,"interventions":2636},"NCT00677677","Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients",[89],"2011-04","2012-12","2008-05",[2635],"Transplant",[2617],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"intervention":2642,"totalTrials":116,"cells":2643},"Rivaroxaban 2.5 MG [Xarelto]",{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2648,"PHASE3":2650,"PHASE4":2662,"NA":2664},{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[2652],{"nctId":2653,"briefTitle":2654,"status":147,"phases":2655,"primaryCompletion":2656,"completion":2657,"start":2658,"enrollment":1147,"conditions":2659,"interventions":2661},"NCT04838808","Rivaroxaban in Type 2 Myocardial Infarctions",[88,89],"2022-05-12","2023-01-03","2021-04-05",[2660],"Type II Myocardial Infarction",[2642],{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":98},[],{"intervention":2667,"totalTrials":116,"cells":2668},"imiquimod 5% cream",{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2686,"NA":2688},{"trials":2670,"activeCount":98},[],{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[2677],{"nctId":2678,"briefTitle":2679,"status":1572,"phases":2680,"completion":2681,"start":2682,"enrollment":98,"conditions":2683,"interventions":2685},"NCT00230373","Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study",[89],"2007-06","2005-11",[2684],"Morphea",[2667],{"trials":2687,"activeCount":98},[],{"trials":2689,"activeCount":98},[],{"intervention":2471,"totalTrials":116,"cells":2691},{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2704,"NA":2706},{"trials":2693,"activeCount":98},[],{"trials":2695,"activeCount":98},[],{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[2700],{"nctId":2462,"briefTitle":2463,"status":1572,"phases":2701,"primaryCompletion":1269,"completion":1269,"start":2465,"enrollment":98,"conditions":2702,"interventions":2703},[88,89],[2467,2468,2469,1273],[2471,2451],{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":98},[],{"intervention":2709,"totalTrials":116,"cells":2710},"CTC",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2729,"NA":2731},{"trials":2712,"activeCount":98},[],{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[2719],{"nctId":2720,"briefTitle":2721,"status":147,"phases":2722,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":1331,"conditions":2725,"interventions":2727},"NCT02980679","A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery",[89],"2019-02-25","2017-03-03",[2726],"Thyroid Gland Diseases",[2709,2728],"G-PERT",{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"intervention":2728,"totalTrials":116,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[],{"trials":2742,"activeCount":98},[2743],{"nctId":2720,"briefTitle":2721,"status":147,"phases":2744,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":1331,"conditions":2745,"interventions":2746},[89],[2726],[2709,2728],{"trials":2748,"activeCount":98},[],{"trials":2750,"activeCount":98},[],{"intervention":2752,"totalTrials":116,"cells":2753},"a combination of MCT, LCT , and Fish Oil",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2771,"NA":2773},{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[2762],{"nctId":2763,"briefTitle":2764,"status":147,"phases":2765,"completion":2214,"start":2682,"enrollment":2766,"conditions":2767,"interventions":2770},"NCT00336908","Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery",[88,89],32,[2768,2769],"Inflammation","Cardiac Surgical Procedures",[2752],{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[],{"intervention":2776,"totalTrials":116,"cells":2777},"Trimethoprim Sulfamethoxazole",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2795,"NA":2797},{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[2786],{"nctId":2787,"briefTitle":2788,"status":1572,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":98,"conditions":2792,"interventions":2794},"NCT00752375","Antibiotic Prophylaxis in Children With Pyelonephritis",[89],"2014-12","2009-02",[2793],"Pyelonephritis",[2776],{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"intervention":2800,"totalTrials":116,"cells":2801},"Acetyl-l-carnitine",{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2820,"NA":2822},{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[2810],{"nctId":2811,"briefTitle":2812,"status":147,"phases":2813,"primaryCompletion":2814,"completion":2303,"start":2815,"enrollment":152,"conditions":2816,"interventions":2819},"NCT02141035","Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome",[88,89],"2017-06","2015-09",[2817,2818],"Carpal Tunnel Syndrome","Compression Neuropathy",[2800],{"trials":2821,"activeCount":98},[],{"trials":2823,"activeCount":98},[],{"intervention":2825,"totalTrials":116,"cells":2826},"Midodrine, albumin, octreotide LAR",{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2833,"PHASE4":2846,"NA":2848},{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[2835],{"nctId":2836,"briefTitle":2837,"status":147,"phases":2838,"completion":2055,"start":2839,"enrollment":2840,"conditions":2841,"interventions":2844},"NCT00240045","The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction",[88,89],"2005-10",9,[2842,2843],"Type 2 Hepatorenal Syndrome","Refractory Ascites",[2825,2845],"midodrine, octreotide, albumin",{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"intervention":2845,"totalTrials":116,"cells":2851},{"EARLY_PHASE1":2852,"PHASE1":2854,"PHASE2":2856,"PHASE3":2858,"PHASE4":2864,"NA":2866},{"trials":2853,"activeCount":98},[],{"trials":2855,"activeCount":98},[],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[2860],{"nctId":2836,"briefTitle":2837,"status":147,"phases":2861,"completion":2055,"start":2839,"enrollment":2840,"conditions":2862,"interventions":2863},[88,89],[2842,2843],[2825,2845],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[],{"intervention":2869,"totalTrials":116,"cells":2870},"Prednisone",{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2877,"PHASE4":2888,"NA":2890},{"trials":2872,"activeCount":98},[],{"trials":2874,"activeCount":98},[],{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[2879],{"nctId":2880,"briefTitle":2881,"status":1572,"phases":2882,"primaryCompletion":2883,"completion":2884,"start":341,"enrollment":98,"conditions":2885,"interventions":2887},"NCT04795583","Corticosteroids for COVID-19",[89],"2022-04","2022-08",[2886],"Covid19",[2869],{"trials":2889,"activeCount":98},[],{"trials":2891,"activeCount":98},[],{"intervention":2893,"totalTrials":116,"cells":2894},"Finasteride",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2911,"NA":2913},{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":98},[2903],{"nctId":2904,"briefTitle":2905,"status":1572,"phases":2906,"primaryCompletion":1665,"completion":1665,"start":2907,"enrollment":98,"conditions":2908,"interventions":2910},"NCT00564460","On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)",[89],"2008-02",[2909],"Benign Prostatic Hyperplasia",[2893],{"trials":2912,"activeCount":98},[],{"trials":2914,"activeCount":98},[],{"intervention":2916,"totalTrials":116,"cells":2917},"Combination antiviral therapy",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2936,"NA":2938},{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"trials":2925,"activeCount":98},[2926],{"nctId":2927,"briefTitle":2928,"status":147,"phases":2929,"completion":2930,"start":2931,"enrollment":2932,"conditions":2933,"interventions":2935},"NCT00490620","Study of Combivir for Patients With Primary Biliary Cirrhosis",[88,89],"2007-04","2004-01",59,[2934],"Primary Biliary Cirrhosis",[2916],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":98},[],{"intervention":2941,"totalTrials":116,"cells":2942},"Insulin",{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2960,"NA":2962},{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"trials":2950,"activeCount":98},[2951],{"nctId":2952,"briefTitle":2953,"status":1572,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":98,"conditions":2957,"interventions":2959},"NCT05321251","Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.",[88,89],"2023-10-18","2022-06-01",[2958],"Neurotrophic Keratitis",[2941],{"trials":2961,"activeCount":98},[],{"trials":2963,"activeCount":98},[],{"intervention":2965,"totalTrials":116,"cells":2966},"Levothyroxine",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2986,"NA":2988},{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[2975],{"nctId":2976,"briefTitle":2977,"status":1572,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":2980,"enrollment":98,"conditions":2981,"interventions":2985},"NCT02548715","Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery",[88,89],"2017-07","2015-07",[2982,2983,2984],"Hypothyroidism","Neoplasms","Postoperative Complications",[2965],{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"intervention":2991,"totalTrials":116,"cells":2992},"alendronate or risedronate",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3011,"NA":3013},{"trials":2994,"activeCount":98},[],{"trials":2996,"activeCount":98},[],{"trials":2998,"activeCount":98},[],{"trials":3000,"activeCount":98},[3001],{"nctId":3002,"briefTitle":3003,"status":147,"phases":3004,"completion":3005,"start":3006,"enrollment":3007,"conditions":3008,"interventions":3010},"NCT00136058","Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients",[89],"2006-04","2002-01",250,[3009],"Osteoporosis",[2991],{"trials":3012,"activeCount":98},[],{"trials":3014,"activeCount":98},[],{"intervention":3016,"totalTrials":116,"cells":3017},"Human normal immunoglobulin G",{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3036,"NA":3038},{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[3026],{"nctId":3027,"briefTitle":3028,"status":147,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":3032,"conditions":3033,"interventions":3035},"NCT02774239","A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)",[89],"2022-10-21","2014-10",26,[3034],"Myasthenia Gravis",[3016],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":98},[],{"intervention":2445,"totalTrials":116,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3054,"NA":3056},{"trials":3043,"activeCount":98},[],{"trials":3045,"activeCount":98},[],{"trials":3047,"activeCount":98},[],{"trials":3049,"activeCount":98},[3050],{"nctId":2436,"briefTitle":2437,"status":147,"phases":3051,"start":2439,"enrollment":628,"conditions":3052,"interventions":3053},[88,89],[2441],[2443,2444,2445],{"trials":3055,"activeCount":98},[],{"trials":3057,"activeCount":98},[],{"intervention":3059,"totalTrials":116,"cells":3060},"Probiotic - VSL#3",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3067,"PHASE4":3077,"NA":3079},{"trials":3062,"activeCount":98},[],{"trials":3064,"activeCount":98},[],{"trials":3066,"activeCount":98},[],{"trials":3068,"activeCount":98},[3069],{"nctId":3070,"briefTitle":3071,"status":147,"phases":3072,"start":3073,"enrollment":806,"conditions":3074,"interventions":3076},"NCT00175292","A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.",[89],"2003-12",[1578,3075],"Inflammatory Bowel Disease",[3059],{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":98},[],{"intervention":3082,"totalTrials":116,"cells":3083},"interferon alpha 2b",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3090,"PHASE4":3100,"NA":3102},{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[],{"trials":3089,"activeCount":98},[],{"trials":3091,"activeCount":98},[3092],{"nctId":3093,"briefTitle":3094,"status":1572,"phases":3095,"enrollment":98,"conditions":3096,"interventions":3099},"NCT00686478","Intron A for the Treatment of Hypertrophic Scar",[89],[3097,3098],"Burn","Hypertrophic Scar",[3082],{"trials":3101,"activeCount":98},[],{"trials":3103,"activeCount":98},[],{"intervention":3105,"totalTrials":116,"cells":3106},"atorvastatin 80 mg per os daily",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3123,"NA":3125},{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[],{"trials":3112,"activeCount":98},[],{"trials":3114,"activeCount":98},[3115],{"nctId":3116,"briefTitle":3117,"status":147,"phases":3118,"primaryCompletion":1289,"completion":3119,"start":2532,"enrollment":312,"conditions":3120,"interventions":3122},"NCT01073800","Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill",[88,89],"2011-09",[2441,23,3121],"Renal Failure",[3105],{"trials":3124,"activeCount":98},[],{"trials":3126,"activeCount":98},[],{"intervention":3128,"totalTrials":116,"cells":3129},"Collegenase",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3146,"NA":3148},{"trials":3131,"activeCount":98},[],{"trials":3133,"activeCount":98},[],{"trials":3135,"activeCount":98},[],{"trials":3137,"activeCount":98},[3138],{"nctId":3139,"briefTitle":3140,"status":1572,"phases":3141,"primaryCompletion":3142,"completion":3142,"start":477,"enrollment":98,"conditions":3143,"interventions":3145},"NCT01776892","Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease",[89],"2014-03",[3144],"Dupuytren Contracture",[3128],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[],{"intervention":3151,"totalTrials":116,"cells":3152},"Dextrose",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3168,"NA":3170},{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[],{"trials":3160,"activeCount":98},[3161],{"nctId":3162,"briefTitle":3163,"status":441,"phases":3164,"primaryCompletion":2476,"completion":2476,"start":2465,"enrollment":16,"conditions":3165,"interventions":3167},"NCT04020601","The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty",[88,89],[3166,1273],"Rotator Cuff Injuries",[1275,3151],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[],{"intervention":3173,"totalTrials":413,"cells":3174},"Nitric Oxide",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3208,"PHASE4":3210,"NA":3212},{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[3181,3190,3199],{"nctId":3182,"briefTitle":3183,"status":1572,"phases":3184,"primaryCompletion":3185,"completion":44,"start":3186,"enrollment":98,"conditions":3187,"interventions":3189},"NCT04181359","The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.",[87,88],"2025-12-01","2024-09-01",[3188],"Dyspnea",[3173],{"nctId":3191,"briefTitle":3192,"status":147,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":152,"conditions":3196,"interventions":3198},"NCT04231773","The Effect of Inhaled Nitric Oxide on Maximal Oxygen Consumption During Exercise in Hypoxia",[87,88],"2021-12-04","2020-08-17",[3197],"Hypoxia",[3173],{"nctId":3200,"briefTitle":3201,"status":147,"phases":3202,"primaryCompletion":3203,"completion":3203,"start":3204,"enrollment":3205,"conditions":3206,"interventions":3207},"NCT03679312","The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD",[87,88],"2023-11-20","2018-09-04",140,[3188],[3173],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"trials":3213,"activeCount":98},[],{"intervention":3215,"totalTrials":413,"cells":3216},"alemtuzumab",{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"trials":3222,"activeCount":98},[3223,3230,3244],{"nctId":3224,"briefTitle":3225,"status":147,"phases":3226,"enrollment":24,"conditions":3227,"interventions":3228},"NCT00175266","Islet Transplantation Using Campath-1H and Infliximab Induction",[88],[18],[3215,3229],"infliximab",{"nctId":3231,"briefTitle":3232,"status":147,"phases":3233,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":3236,"conditions":3237,"interventions":3239},"NCT03182426","Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)",[87,88],"2024-07-15","2017-08-15",22,[3238],"Diabetes Mellitus, Type 1",[3240,3241,3242,2504,3243],"Plerixafor","Alemtuzumab","Anakinra","Liraglutide",{"nctId":3245,"briefTitle":3246,"status":147,"phases":3247,"completion":3248,"start":2682,"enrollment":24,"conditions":3249,"interventions":3250},"NCT00175253","Alemtuzumab Induction in Islet Transplantation",[88],"2012-04",[18],[3215],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":98},[],{"trials":3256,"activeCount":98},[],{"intervention":2504,"totalTrials":94,"cells":3258},{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3260,"activeCount":98},[],{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[3265,3269],{"nctId":3231,"briefTitle":3232,"status":147,"phases":3266,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":3236,"conditions":3267,"interventions":3268},[87,88],[3238],[3240,3241,3242,2504,3243],{"nctId":2495,"briefTitle":2496,"status":147,"phases":3270,"primaryCompletion":2498,"completion":2498,"start":1890,"enrollment":319,"conditions":3271,"interventions":3272},[87,88],[18],[2501,2502,2503,2504,2486],{"trials":3274,"activeCount":98},[],{"trials":3276,"activeCount":98},[],{"trials":3278,"activeCount":98},[],{"intervention":3280,"totalTrials":94,"cells":3281},"FMT",{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3283,"activeCount":98},[],{"trials":3285,"activeCount":98},[],{"trials":3287,"activeCount":98},[3288,3297],{"nctId":3289,"briefTitle":3290,"status":147,"phases":3291,"primaryCompletion":3292,"completion":3293,"start":3294,"enrollment":413,"conditions":3295,"interventions":3296},"NCT03439982","Fecal Transplant for Hepatic Encephalopathy",[87,88],"2019-08-07","2021-03-18","2016-04-12",[2396],[3280],{"nctId":3298,"briefTitle":3299,"status":147,"phases":3300,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":3304,"conditions":3305,"interventions":3306},"NCT03477916","Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.",[88],"2020-06-01","2020-12-31","2018-04-09",68,[26,220],[3280],{"trials":3308,"activeCount":98},[],{"trials":3310,"activeCount":98},[],{"trials":3312,"activeCount":98},[],{"intervention":3314,"totalTrials":94,"cells":3315},"labetalol\u002Fhydralazine\u002Fenalapril",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[3322,3333],{"nctId":3323,"briefTitle":3324,"status":441,"phases":3325,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3332},"NCT02281838","The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II",[88],"2021-11","2021-12","2011-08-01",142,[3331],"Intracerebral Hemorrhage",[3314],{"nctId":3334,"briefTitle":3335,"status":147,"phases":3336,"primaryCompletion":1288,"completion":1159,"start":3337,"enrollment":3338,"conditions":3339,"interventions":3340},"NCT00963976","Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial",[88],"2007-01",74,[3331],[3314],{"trials":3342,"activeCount":98},[],{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[],{"intervention":3348,"totalTrials":116,"cells":3349},"Periostat",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3351,"activeCount":98},[],{"trials":3353,"activeCount":98},[],{"trials":3355,"activeCount":98},[3356],{"nctId":3357,"briefTitle":3358,"status":147,"phases":3359,"primaryCompletion":2633,"completion":2533,"start":2839,"enrollment":1981,"conditions":3360,"interventions":3364},"NCT00246740","Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting",[88],[3361,3362,3363],"Coronary Artery Bypass Grafting","Cardiopulmonary Bypass","Reperfusion Injury",[3348],{"trials":3366,"activeCount":98},[],{"trials":3368,"activeCount":98},[],{"trials":3370,"activeCount":98},[],{"intervention":1162,"totalTrials":116,"cells":3372},{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3377,"PHASE3":3383,"PHASE4":3385,"NA":3387},{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"trials":3378,"activeCount":98},[3379],{"nctId":1155,"briefTitle":1156,"status":441,"phases":3380,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":413,"conditions":3381,"interventions":3382},[88],[853],[40,1162],{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[],{"intervention":3390,"totalTrials":116,"cells":3391},"Acetylsalicylic acid",{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[3398],{"nctId":3399,"briefTitle":3400,"status":147,"phases":3401,"primaryCompletion":3402,"completion":3402,"start":3403,"enrollment":628,"conditions":3404,"interventions":3407},"NCT02295826","Dabigatran Following Transient Ischemic Attack and Minor Stroke",[88],"2018-12-18","2015-01",[3405,3406],"Transient Ischemic Attack","Minor Ischemic Stroke",[3408,3390],"Dabigatran",{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[],{"trials":3414,"activeCount":98},[],{"intervention":3416,"totalTrials":116,"cells":3417},"Dabigatran 110\u002F150 mg BID",{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3432,"PHASE4":3434,"NA":3436},{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"trials":3423,"activeCount":98},[3424],{"nctId":3425,"briefTitle":3426,"status":147,"phases":3427,"primaryCompletion":3428,"completion":3428,"start":1159,"enrollment":3429,"conditions":3430,"interventions":3431},"NCT01769703","Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke",[88],"2014-05",53,[3405,3406],[3416],{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"intervention":3439,"totalTrials":116,"cells":3440},"Emtricitabine",{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[],{"trials":3446,"activeCount":98},[3447],{"nctId":3448,"briefTitle":3449,"status":147,"phases":3450,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":3454,"conditions":3455,"interventions":3457},"NCT03954327","Combination Antiretroviral Therapy (cART) for PBC",[88],"2022-10-01","2024-01-01","2021-03-01",37,[3456],"Primary Biliary Cholangitis",[3439,3458],"Raltegravir",{"trials":3460,"activeCount":98},[],{"trials":3462,"activeCount":98},[],{"trials":3464,"activeCount":98},[],{"intervention":3458,"totalTrials":116,"cells":3466},{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3468,"activeCount":98},[],{"trials":3470,"activeCount":98},[],{"trials":3472,"activeCount":98},[3473],{"nctId":3448,"briefTitle":3449,"status":147,"phases":3474,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":3454,"conditions":3475,"interventions":3476},[88],[3456],[3439,3458],{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[],{"trials":3482,"activeCount":98},[],{"intervention":3484,"totalTrials":116,"cells":3485},"Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3487,"activeCount":98},[],{"trials":3489,"activeCount":98},[],{"trials":3491,"activeCount":98},[3492],{"nctId":3493,"briefTitle":3494,"status":147,"phases":3495,"primaryCompletion":3496,"completion":3496,"start":3497,"enrollment":3498,"conditions":3499,"interventions":3501},"NCT04717193","Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis",[88],"2023-04-17","2021-05-28",42,[3500],"Appendicitis Acute",[3484],{"trials":3503,"activeCount":98},[],{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"intervention":3509,"totalTrials":116,"cells":3510},"Alpha-1 Antitrypsin",{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3512,"activeCount":98},[],{"trials":3514,"activeCount":98},[],{"trials":3516,"activeCount":98},[3517],{"nctId":3518,"briefTitle":3519,"status":147,"phases":3520,"primaryCompletion":3521,"completion":3521,"start":3522,"enrollment":2356,"conditions":3523,"interventions":3524},"NCT02520076","Aralast NP in Islet Transplant",[87,88],"2019-09-30","2015-08",[966],[3509],{"trials":3526,"activeCount":98},[],{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"intervention":3532,"totalTrials":116,"cells":3533},"Fidaxomicin 200 mg",{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3538,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3535,"activeCount":98},[],{"trials":3537,"activeCount":98},[],{"trials":3539,"activeCount":98},[3540],{"nctId":3541,"briefTitle":3542,"status":441,"phases":3543,"primaryCompletion":3544,"completion":3544,"start":3545,"enrollment":319,"conditions":3546,"interventions":3548},"NCT03760484","Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection",[88],"2020-03-10","2019-01-21",[3547],"Clostridium Difficile",[3532,3549],"fecal microbiota transplantation",{"trials":3551,"activeCount":98},[],{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[],{"intervention":3549,"totalTrials":116,"cells":3557},{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[3564],{"nctId":3541,"briefTitle":3542,"status":441,"phases":3565,"primaryCompletion":3544,"completion":3544,"start":3545,"enrollment":319,"conditions":3566,"interventions":3567},[88],[3547],[3532,3549],{"trials":3569,"activeCount":98},[],{"trials":3571,"activeCount":98},[],{"trials":3573,"activeCount":98},[],{"intervention":3240,"totalTrials":116,"cells":3575},{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[3582],{"nctId":3231,"briefTitle":3232,"status":147,"phases":3583,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":3236,"conditions":3584,"interventions":3585},[87,88],[3238],[3240,3241,3242,2504,3243],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[],{"trials":3591,"activeCount":98},[],{"intervention":3242,"totalTrials":116,"cells":3593},{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3595,"activeCount":98},[],{"trials":3597,"activeCount":98},[],{"trials":3599,"activeCount":98},[3600],{"nctId":3231,"briefTitle":3232,"status":147,"phases":3601,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":3236,"conditions":3602,"interventions":3603},[87,88],[3238],[3240,3241,3242,2504,3243],{"trials":3605,"activeCount":98},[],{"trials":3607,"activeCount":98},[],{"trials":3609,"activeCount":98},[],{"intervention":3243,"totalTrials":116,"cells":3611},{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3613,"activeCount":98},[],{"trials":3615,"activeCount":98},[],{"trials":3617,"activeCount":98},[3618],{"nctId":3231,"briefTitle":3232,"status":147,"phases":3619,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":3236,"conditions":3620,"interventions":3621},[87,88],[3238],[3240,3241,3242,2504,3243],{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[],{"intervention":3629,"totalTrials":116,"cells":3630},"Ropinirole",{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3632,"activeCount":98},[],{"trials":3634,"activeCount":98},[],{"trials":3636,"activeCount":98},[3637],{"nctId":3638,"briefTitle":3639,"status":441,"phases":3640,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":413,"conditions":3644,"interventions":3647},"NCT03708237","Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD",[88],"2019-11-06","2019-12-11","2019-02-19",[3645,3646],"Restless Legs Syndrome","End Stage Renal Disease",[3629,3648,3649],"Gabapentin","Placebos",{"trials":3651,"activeCount":98},[],{"trials":3653,"activeCount":98},[],{"trials":3655,"activeCount":98},[],{"intervention":3648,"totalTrials":116,"cells":3657},{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3659,"activeCount":98},[],{"trials":3661,"activeCount":98},[],{"trials":3663,"activeCount":98},[3664],{"nctId":3638,"briefTitle":3639,"status":441,"phases":3665,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":413,"conditions":3666,"interventions":3667},[88],[3645,3646],[3629,3648,3649],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"intervention":3675,"totalTrials":116,"cells":3676},"Memantine",{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3691,"PHASE4":3693,"NA":3695},{"trials":3678,"activeCount":98},[],{"trials":3680,"activeCount":98},[],{"trials":3682,"activeCount":98},[3683],{"nctId":3684,"briefTitle":3685,"status":147,"phases":3686,"primaryCompletion":2030,"completion":2030,"start":3687,"enrollment":3498,"conditions":3688,"interventions":3690},"NCT00409721","The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)",[88],"2007-03",[3689],"Amyotrophic Lateral Sclerosis",[3675],{"trials":3692,"activeCount":98},[],{"trials":3694,"activeCount":98},[],{"trials":3696,"activeCount":98},[],{"intervention":3698,"totalTrials":116,"cells":3699},"Lyophilized fecal microbiota transplant",{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3704,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[3706],{"nctId":3707,"briefTitle":3708,"status":147,"phases":3709,"primaryCompletion":3710,"completion":3710,"start":3711,"enrollment":3712,"conditions":3713,"interventions":3716},"NCT03806803","Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection",[88],"2024-03-12","2019-03-21",138,[3714,3715],"Clostridia Difficile Colitis","Clostridium Difficile Diarrhea",[3698,3717],"Lyophilized sterile fecal filtrate",{"trials":3719,"activeCount":98},[],{"trials":3721,"activeCount":98},[],{"trials":3723,"activeCount":98},[],{"intervention":3717,"totalTrials":116,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3727,"activeCount":98},[],{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[3732],{"nctId":3707,"briefTitle":3708,"status":147,"phases":3733,"primaryCompletion":3710,"completion":3710,"start":3711,"enrollment":3712,"conditions":3734,"interventions":3735},[88],[3714,3715],[3698,3717],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[],{"trials":3741,"activeCount":98},[],{"intervention":3743,"totalTrials":116,"cells":3744},"perindopril OR bisoprolol OR placebo",{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3749,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3746,"activeCount":98},[],{"trials":3748,"activeCount":98},[],{"trials":3750,"activeCount":98},[3751],{"nctId":3752,"briefTitle":3753,"status":3754,"phases":3755,"primaryCompletion":2815,"completion":1158,"start":3756,"enrollment":3757,"conditions":3758,"interventions":3759},"NCT01016886","Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research","UNKNOWN",[87,88],"2010-09",99,[21,15],[3743],{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[],{"intervention":3767,"totalTrials":116,"cells":3768},"Fecal Microbial Transplant",{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3773,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3770,"activeCount":98},[],{"trials":3772,"activeCount":98},[],{"trials":3774,"activeCount":98},[3775],{"nctId":3776,"briefTitle":3777,"status":147,"phases":3778,"primaryCompletion":3779,"completion":3779,"start":3780,"enrollment":3304,"conditions":3781,"interventions":3782},"NCT03727321","FMT and Fiber in Patients With Metabolic Syndrome",[88],"2020-01-16","2018-07-01",[26,220],[3767],{"trials":3784,"activeCount":98},[],{"trials":3786,"activeCount":98},[],{"trials":3788,"activeCount":98},[],{"intervention":3790,"totalTrials":116,"cells":3791},"Streptokinase",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3793,"activeCount":98},[],{"trials":3795,"activeCount":98},[],{"trials":3797,"activeCount":98},[3798],{"nctId":3799,"briefTitle":3800,"status":1572,"phases":3801,"primaryCompletion":2256,"completion":1158,"start":3802,"enrollment":98,"conditions":3803,"interventions":3804},"NCT02150785","Asia Africa Streptokinase Trial",[88],"2014-06",[1743],[3790],{"trials":3806,"activeCount":98},[],{"trials":3808,"activeCount":98},[],{"trials":3810,"activeCount":98},[],{"intervention":3812,"totalTrials":116,"cells":3813},"Testosterone",{"EARLY_PHASE1":3814,"PHASE1":3816,"PHASE2":3818,"PHASE3":3827,"PHASE4":3829,"NA":3831},{"trials":3815,"activeCount":98},[],{"trials":3817,"activeCount":98},[],{"trials":3819,"activeCount":98},[3820],{"nctId":3821,"briefTitle":3822,"status":441,"phases":3823,"primaryCompletion":2004,"completion":2004,"start":1255,"enrollment":3824,"conditions":3825,"interventions":3826},"NCT01469988","The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial",[88],318,[15],[3812],{"trials":3828,"activeCount":98},[],{"trials":3830,"activeCount":98},[],{"trials":3832,"activeCount":98},[],{"intervention":3834,"totalTrials":116,"cells":3835},"Intravenous N-Acetylcysteine",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[3842],{"nctId":3843,"briefTitle":3844,"status":147,"phases":3845,"primaryCompletion":3846,"completion":1269,"start":3847,"enrollment":3848,"conditions":3849,"interventions":3851},"NCT04023266","A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI",[88],"2020-11-15","2019-09-20",44,[3850],"STEMI",[3834],{"trials":3853,"activeCount":98},[],{"trials":3855,"activeCount":98},[],{"trials":3857,"activeCount":98},[],{"intervention":3859,"totalTrials":116,"cells":3860},"Nefopam",{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[3867],{"nctId":3868,"briefTitle":3869,"status":147,"phases":3870,"primaryCompletion":3871,"completion":3871,"start":3872,"enrollment":697,"conditions":3873,"interventions":3877},"NCT04685577","Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients",[88],"2026-03-31","2022-07-10",[3874,3875,3876],"Burn; Multiple Body Regions, Max. Second Degree","Third-Degree Burn","Burn Degree Second",[3859],{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"intervention":3885,"totalTrials":116,"cells":3886},"Definity® with High Mechanical Index Ultrasound",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3903,"PHASE4":3905,"NA":3907},{"trials":3888,"activeCount":98},[],{"trials":3890,"activeCount":98},[],{"trials":3892,"activeCount":98},[3893],{"nctId":3894,"briefTitle":3895,"status":441,"phases":3896,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":3899,"conditions":3900,"interventions":3902},"NCT04217304","SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial",[88],"2026-01-19","2021-02-23",41,[3901],"ST Elevation Myocardial Infarction",[3885],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"trials":3908,"activeCount":98},[],{"intervention":3910,"totalTrials":116,"cells":3911},"IDN-6556",{"EARLY_PHASE1":3912,"PHASE1":3914,"PHASE2":3916,"PHASE3":3926,"PHASE4":3928,"NA":3930},{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[3918],{"nctId":3919,"briefTitle":3920,"status":147,"phases":3921,"primaryCompletion":2256,"completion":2256,"start":3922,"enrollment":24,"conditions":3923,"interventions":3925},"NCT01653899","Caspase Inhibition in Islet Transplantation",[87,88],"2012-06",[3924],"Diabetes",[3910],{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[],{"trials":3931,"activeCount":98},[],{"intervention":3933,"totalTrials":116,"cells":3934},"rAAV2.REP1 vector",{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3939,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"trials":3940,"activeCount":98},[3941],{"nctId":3942,"briefTitle":3943,"status":147,"phases":3944,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":1235,"conditions":3948,"interventions":3950},"NCT02077361","An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia",[87,88],"2017-08-30","2022-05-16","2015-04",[3949],"Choroideremia",[3933],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[],{"trials":3956,"activeCount":98},[],{"intervention":2501,"totalTrials":116,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3960,"activeCount":98},[],{"trials":3962,"activeCount":98},[],{"trials":3964,"activeCount":98},[3965],{"nctId":2495,"briefTitle":2496,"status":147,"phases":3966,"primaryCompletion":2498,"completion":2498,"start":1890,"enrollment":319,"conditions":3967,"interventions":3968},[87,88],[18],[2501,2502,2503,2504,2486],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"trials":3974,"activeCount":98},[],{"intervention":2502,"totalTrials":116,"cells":3976},{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3981,"PHASE3":3987,"PHASE4":3989,"NA":3991},{"trials":3978,"activeCount":98},[],{"trials":3980,"activeCount":98},[],{"trials":3982,"activeCount":98},[3983],{"nctId":2495,"briefTitle":2496,"status":147,"phases":3984,"primaryCompletion":2498,"completion":2498,"start":1890,"enrollment":319,"conditions":3985,"interventions":3986},[87,88],[18],[2501,2502,2503,2504,2486],{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[],{"trials":3992,"activeCount":98},[],{"intervention":2503,"totalTrials":116,"cells":3994},{"EARLY_PHASE1":3995,"PHASE1":3997,"PHASE2":3999,"PHASE3":4005,"PHASE4":4007,"NA":4009},{"trials":3996,"activeCount":98},[],{"trials":3998,"activeCount":98},[],{"trials":4000,"activeCount":98},[4001],{"nctId":2495,"briefTitle":2496,"status":147,"phases":4002,"primaryCompletion":2498,"completion":2498,"start":1890,"enrollment":319,"conditions":4003,"interventions":4004},[87,88],[18],[2501,2502,2503,2504,2486],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"intervention":4012,"totalTrials":116,"cells":4013},"Sildenafil 50 mg",{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4015,"activeCount":98},[],{"trials":4017,"activeCount":98},[],{"trials":4019,"activeCount":98},[4020],{"nctId":4021,"briefTitle":4022,"status":147,"phases":4023,"primaryCompletion":4024,"completion":4024,"start":4025,"enrollment":3032,"conditions":4026,"interventions":4028},"NCT04985929","The Impact of Sildenafil on the Pulmonary Circulation in Healthy Trained and Untrained Humans",[88],"2024-07-05","2021-07-01",[4027],"Healthy",[4012],{"trials":4030,"activeCount":98},[],{"trials":4032,"activeCount":98},[],{"trials":4034,"activeCount":98},[],{"intervention":4036,"totalTrials":116,"cells":4037},"fesoterodine 4mg",{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4057,"PHASE4":4059,"NA":4061},{"trials":4039,"activeCount":98},[],{"trials":4041,"activeCount":98},[],{"trials":4043,"activeCount":98},[4044],{"nctId":4045,"briefTitle":4046,"status":147,"phases":4047,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4054},"NCT02240459","A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment",[88],"2020-01-31","2016-08",47,[4052,4053],"Overactive Bladder","Mild Cognitive Impairment",[4036,4055,4056],"Oxybutynin","fesoterodine 8mg",{"trials":4058,"activeCount":98},[],{"trials":4060,"activeCount":98},[],{"trials":4062,"activeCount":98},[],{"intervention":4055,"totalTrials":116,"cells":4064},{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4066,"activeCount":98},[],{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[4071],{"nctId":4045,"briefTitle":4046,"status":147,"phases":4072,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4073,"interventions":4074},[88],[4052,4053],[4036,4055,4056],{"trials":4076,"activeCount":98},[],{"trials":4078,"activeCount":98},[],{"trials":4080,"activeCount":98},[],{"intervention":4056,"totalTrials":116,"cells":4082},{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4087,"PHASE3":4093,"PHASE4":4095,"NA":4097},{"trials":4084,"activeCount":98},[],{"trials":4086,"activeCount":98},[],{"trials":4088,"activeCount":98},[4089],{"nctId":4045,"briefTitle":4046,"status":147,"phases":4090,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4091,"interventions":4092},[88],[4052,4053],[4036,4055,4056],{"trials":4094,"activeCount":98},[],{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[],{"intervention":4100,"totalTrials":116,"cells":4101},"Vitamin D3",{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[4108],{"nctId":4109,"briefTitle":4110,"status":147,"phases":4111,"primaryCompletion":2790,"completion":2255,"start":4112,"enrollment":806,"conditions":4113,"interventions":4117},"NCT01476501","Vitamin D Supplementation in Diabetic Nephropathy",[88],"2011-10",[4114,4115,4116],"Sub-optimal Vitamin D Status","Bone Disease","Diabetic Nephropathy",[4100],{"trials":4119,"activeCount":98},[],{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"intervention":4125,"totalTrials":116,"cells":4126},"Vancomycin",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4128,"activeCount":98},[],{"trials":4130,"activeCount":98},[],{"trials":4132,"activeCount":98},[4133],{"nctId":4134,"briefTitle":4135,"status":441,"phases":4136,"primaryCompletion":4137,"completion":4137,"start":4138,"enrollment":4139,"conditions":4140,"interventions":4142},"NCT02374853","Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)",[88],"2019-04","2015-03",1037,[4141],"INFECTION",[4125],{"trials":4144,"activeCount":98},[],{"trials":4146,"activeCount":98},[],{"trials":4148,"activeCount":98},[],{"intervention":4150,"totalTrials":116,"cells":4151},"[131]I-IAZA",{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4153,"activeCount":98},[],{"trials":4155,"activeCount":98},[],{"trials":4157,"activeCount":98},[4158],{"nctId":4159,"briefTitle":4160,"status":1572,"phases":4161,"primaryCompletion":4162,"completion":4162,"start":4163,"enrollment":98,"conditions":4164,"interventions":4167},"NCT03427320","Imaging of Advanced Tumours Using [131]I-IAZA",[87,88],"2021-04","2018-12",[4165,4166],"Locally Advanced Solid Tumors","Metastatic Solid Tumors",[4150],{"trials":4169,"activeCount":98},[],{"trials":4171,"activeCount":98},[],{"trials":4173,"activeCount":98},[],{"intervention":4175,"totalTrials":116,"cells":4176},"Simvastatin",{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4178,"activeCount":98},[],{"trials":4180,"activeCount":98},[],{"trials":4182,"activeCount":98},[4183],{"nctId":4184,"briefTitle":4185,"status":441,"phases":4186,"primaryCompletion":478,"completion":478,"start":2632,"enrollment":94,"conditions":4187,"interventions":4188},"NCT01654562","The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia",[87,88],[3949],[4175],{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[],{"trials":4194,"activeCount":98},[],{"intervention":4196,"totalTrials":116,"cells":4197},"Dichloroacetate",{"EARLY_PHASE1":4198,"PHASE1":4200,"PHASE2":4202,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4199,"activeCount":98},[],{"trials":4201,"activeCount":98},[],{"trials":4203,"activeCount":98},[4204],{"nctId":4205,"briefTitle":4206,"status":147,"phases":4207,"primaryCompletion":1289,"completion":1289,"start":4208,"enrollment":672,"conditions":4209,"interventions":4211},"NCT00540176","The Safety and Efficacy of DCA for the Treatment of Brain Cancer",[88],"2007-10",[4210],"Malignant Gliomas, Glioblastoma Multiforme",[4196],{"trials":4213,"activeCount":98},[],{"trials":4215,"activeCount":98},[],{"trials":4217,"activeCount":98},[],{"intervention":4219,"totalTrials":116,"cells":4220},"p*17-K4S2",{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4222,"activeCount":98},[],{"trials":4224,"activeCount":98},[],{"trials":4226,"activeCount":98},[4227],{"nctId":4228,"briefTitle":4229,"status":147,"phases":4230,"primaryCompletion":4231,"completion":4231,"start":4232,"enrollment":263,"conditions":4233,"interventions":4235},"NCT04882514","A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals.",[87,88],"2025-05-12","2022-11-07",[4234],"Group A Streptococcal Infection",[4219,4236,4237],"J8-K4S2","Rabavert vaccine",{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[],{"trials":4243,"activeCount":98},[],{"intervention":4236,"totalTrials":116,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4247,"activeCount":98},[],{"trials":4249,"activeCount":98},[],{"trials":4251,"activeCount":98},[4252],{"nctId":4228,"briefTitle":4229,"status":147,"phases":4253,"primaryCompletion":4231,"completion":4231,"start":4232,"enrollment":263,"conditions":4254,"interventions":4255},[87,88],[4234],[4219,4236,4237],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"intervention":4237,"totalTrials":116,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":98},[],{"trials":4267,"activeCount":98},[],{"trials":4269,"activeCount":98},[4270],{"nctId":4228,"briefTitle":4229,"status":147,"phases":4271,"primaryCompletion":4231,"completion":4231,"start":4232,"enrollment":263,"conditions":4272,"interventions":4273},[87,88],[4234],[4219,4236,4237],{"trials":4275,"activeCount":98},[],{"trials":4277,"activeCount":98},[],{"trials":4279,"activeCount":98},[],{"intervention":4281,"totalTrials":116,"cells":4282},"Nitroglycerin",{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4287,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[],{"trials":4288,"activeCount":98},[4289],{"nctId":4290,"briefTitle":4291,"status":147,"phases":4292,"primaryCompletion":2980,"completion":3522,"start":4293,"enrollment":4294,"conditions":4295,"interventions":4297},"NCT02327793","Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke",[88],"2009-06",65,[4296],"Stroke, Acute",[4281,4298],"Labetalol",{"trials":4300,"activeCount":98},[],{"trials":4302,"activeCount":98},[],{"trials":4304,"activeCount":98},[],{"intervention":4298,"totalTrials":116,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4308,"activeCount":98},[],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[4313],{"nctId":4290,"briefTitle":4291,"status":147,"phases":4314,"primaryCompletion":2980,"completion":3522,"start":4293,"enrollment":4294,"conditions":4315,"interventions":4316},[88],[4296],[4281,4298],{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[],{"intervention":4324,"totalTrials":116,"cells":4325},"Resveratrol",{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[],{"trials":4331,"activeCount":98},[4332],{"nctId":4333,"briefTitle":4334,"status":147,"phases":4335,"primaryCompletion":4336,"completion":4336,"start":4337,"enrollment":19,"conditions":4338,"interventions":4340},"NCT03525379","Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure",[88],"2019-10-08","2017-10-26",[4339],"Congestive Heart Failure Chronic",[4324],{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[],{"trials":4346,"activeCount":98},[],{"intervention":4348,"totalTrials":116,"cells":4349},"Ibuprofen",{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4354,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[],{"trials":4355,"activeCount":98},[4356],{"nctId":4357,"briefTitle":4358,"status":147,"phases":4359,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":4363,"conditions":4364,"interventions":4366},"NCT03767933","Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries",[88],"2023-03-09","2023-03-22","2019-04-20",710,[4365],"Musculoskeletal Injury",[4348,4367,4368,4369,4370],"Acetaminophen","Hydromorphone","Acetaminophen placebo","Hydromorphone placebo",{"trials":4372,"activeCount":98},[],{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"intervention":4367,"totalTrials":116,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4383,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4380,"activeCount":98},[],{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385],{"nctId":4357,"briefTitle":4358,"status":147,"phases":4386,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":4363,"conditions":4387,"interventions":4388},[88],[4365],[4348,4367,4368,4369,4370],{"trials":4390,"activeCount":98},[],{"trials":4392,"activeCount":98},[],{"trials":4394,"activeCount":98},[],{"intervention":4369,"totalTrials":116,"cells":4396},{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4407,"PHASE4":4409,"NA":4411},{"trials":4398,"activeCount":98},[],{"trials":4400,"activeCount":98},[],{"trials":4402,"activeCount":98},[4403],{"nctId":4357,"briefTitle":4358,"status":147,"phases":4404,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":4363,"conditions":4405,"interventions":4406},[88],[4365],[4348,4367,4368,4369,4370],{"trials":4408,"activeCount":98},[],{"trials":4410,"activeCount":98},[],{"trials":4412,"activeCount":98},[],{"intervention":4370,"totalTrials":116,"cells":4414},{"EARLY_PHASE1":4415,"PHASE1":4417,"PHASE2":4419,"PHASE3":4425,"PHASE4":4427,"NA":4429},{"trials":4416,"activeCount":98},[],{"trials":4418,"activeCount":98},[],{"trials":4420,"activeCount":98},[4421],{"nctId":4357,"briefTitle":4358,"status":147,"phases":4422,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":4363,"conditions":4423,"interventions":4424},[88],[4365],[4348,4367,4368,4369,4370],{"trials":4426,"activeCount":98},[],{"trials":4428,"activeCount":98},[],{"trials":4430,"activeCount":98},[],{"intervention":4432,"totalTrials":116,"cells":4433},"Baclofen",{"EARLY_PHASE1":4434,"PHASE1":4436,"PHASE2":4438,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[4440],{"nctId":4441,"briefTitle":4442,"status":1572,"phases":4443,"primaryCompletion":4444,"completion":4444,"start":4445,"enrollment":98,"conditions":4446,"interventions":4448},"NCT04471714","Effects of Baclofen on Presynaptic Inhibition in Humans",[88],"2022-03-17","2020-01-10",[4447,568],"Spasticity, Muscle",[4432],{"trials":4450,"activeCount":98},[],{"trials":4452,"activeCount":98},[],{"trials":4454,"activeCount":98},[],{"intervention":4456,"totalTrials":116,"cells":4457},"ACE\u002FARB continuation",{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":98},[4464],{"nctId":4465,"briefTitle":4466,"status":147,"phases":4467,"primaryCompletion":4468,"completion":4468,"start":2004,"enrollment":4469,"conditions":4470,"interventions":4472},"NCT02096406","Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass",[88],"2018-03",126,[4471],"Coronary Artery Disease",[4456,4473],"ACE\u002FARB withdrawal",{"trials":4475,"activeCount":98},[],{"trials":4477,"activeCount":98},[],{"trials":4479,"activeCount":98},[],{"intervention":4473,"totalTrials":116,"cells":4481},{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4483,"activeCount":98},[],{"trials":4485,"activeCount":98},[],{"trials":4487,"activeCount":98},[4488],{"nctId":4465,"briefTitle":4466,"status":147,"phases":4489,"primaryCompletion":4468,"completion":4468,"start":2004,"enrollment":4469,"conditions":4490,"interventions":4491},[88],[4471],[4456,4473],{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"trials":4497,"activeCount":98},[],{"intervention":4499,"totalTrials":116,"cells":4500},"Doxycycline Hyclate",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4502,"activeCount":98},[],{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[4507],{"nctId":4508,"briefTitle":4509,"status":147,"phases":4510,"primaryCompletion":4511,"completion":4512,"start":4513,"enrollment":4514,"conditions":4515,"interventions":4517},"NCT03508232","Doxycycline to Protect Heart Muscle After Heart Attacks",[88],"2025-07-26","2025-08-26","2020-01-06",174,[4516,15],"ST Segment Elevation Myocardial Infarction",[4499],{"trials":4519,"activeCount":98},[],{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[],{"intervention":4525,"totalTrials":116,"cells":4526},"Pantoprazole",{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4531,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4528,"activeCount":98},[],{"trials":4530,"activeCount":98},[],{"trials":4532,"activeCount":98},[4533],{"nctId":4534,"briefTitle":4535,"status":147,"phases":4536,"primaryCompletion":4537,"completion":1288,"start":4538,"enrollment":1147,"conditions":4539,"interventions":4540},"NCT00768651","Incretin Effect and Use After Clinical Islet Transplantation",[88],"2011-07","2008-10",[18],[4525,4541],"Sitagliptin",{"trials":4543,"activeCount":98},[],{"trials":4545,"activeCount":98},[],{"trials":4547,"activeCount":98},[],{"intervention":4541,"totalTrials":116,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4554,"PHASE3":4560,"PHASE4":4562,"NA":4564},{"trials":4551,"activeCount":98},[],{"trials":4553,"activeCount":98},[],{"trials":4555,"activeCount":98},[4556],{"nctId":4534,"briefTitle":4535,"status":147,"phases":4557,"primaryCompletion":4537,"completion":1288,"start":4538,"enrollment":1147,"conditions":4558,"interventions":4559},[88],[18],[4525,4541],{"trials":4561,"activeCount":98},[],{"trials":4563,"activeCount":98},[],{"trials":4565,"activeCount":98},[],{"intervention":4567,"totalTrials":116,"cells":4568},"Probiotic",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[4575],{"nctId":4576,"briefTitle":4577,"status":147,"phases":4578,"primaryCompletion":4579,"completion":4579,"start":4580,"enrollment":4581,"conditions":4582,"interventions":4584},"NCT01032941","The Effect of Probiotics (VSL) on Portal Hypertension",[87,88],"2011-06","2009-12",18,[4583],"Portal Hypertension",[4567],{"trials":4586,"activeCount":98},[],{"trials":4588,"activeCount":98},[],{"trials":4590,"activeCount":98},[],{"intervention":4592,"totalTrials":116,"cells":4593},"Essential oils infused Perineal Hygiene wipe",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4595,"activeCount":98},[],{"trials":4597,"activeCount":98},[4598],{"nctId":4599,"briefTitle":4600,"status":1572,"phases":4601,"primaryCompletion":4602,"completion":4602,"start":4602,"enrollment":98,"conditions":4603,"interventions":4605},"NCT02509403","An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel",[87],"2020-01",[4604],"Urinary Tract Infections",[4592],{"trials":4607,"activeCount":98},[],{"trials":4609,"activeCount":98},[],{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"intervention":4615,"totalTrials":116,"cells":4616},"verapamil",{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4618,"activeCount":98},[],{"trials":4620,"activeCount":98},[4621],{"nctId":4622,"briefTitle":4623,"status":147,"phases":4624,"conditions":4625,"interventions":4626},"NCT01261286","Drug-Disease Interaction in Crohn's Disease",[87],[1578],[4615],{"trials":4628,"activeCount":98},[],{"trials":4630,"activeCount":98},[],{"trials":4632,"activeCount":98},[],{"trials":4634,"activeCount":98},[],{"intervention":4636,"totalTrials":116,"cells":4637},"Dichloroacetate Sodium",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4651,"PHASE3":4653,"PHASE4":4655,"NA":4657},{"trials":4639,"activeCount":98},[],{"trials":4641,"activeCount":98},[4642],{"nctId":4643,"briefTitle":4644,"status":147,"phases":4645,"primaryCompletion":4646,"completion":4646,"start":4647,"enrollment":263,"conditions":4648,"interventions":4650},"NCT01083524","Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension",[87],"2013-09","2010-03",[4649],"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",[4636,4636,4636],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"trials":4656,"activeCount":98},[],{"trials":4658,"activeCount":98},[],{"intervention":4660,"totalTrials":116,"cells":4661},"Transforaminal epidural steroid",{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4676,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4663,"activeCount":98},[],{"trials":4665,"activeCount":98},[4666],{"nctId":4667,"briefTitle":4668,"status":441,"phases":4669,"primaryCompletion":4048,"completion":4048,"start":4670,"enrollment":189,"conditions":4671,"interventions":4675},"NCT02951377","Mechanical Diagnosis and Treatment and\u002For Steroid Injections for Lumbar Radiculopathy",[87],"2017-10-01",[4672,4673,4674],"Sciatica","Lumbosacral Radiculopathy","Lumbar Disc Rupture",[4660],{"trials":4677,"activeCount":98},[],{"trials":4679,"activeCount":98},[],{"trials":4681,"activeCount":98},[],{"trials":4683,"activeCount":98},[],{"intervention":4685,"totalTrials":116,"cells":4686},"Islet isolation using BMX-010",{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4698,"PHASE3":4700,"PHASE4":4702,"NA":4704},{"trials":4688,"activeCount":98},[],{"trials":4690,"activeCount":98},[4691],{"nctId":4692,"briefTitle":4693,"status":147,"phases":4694,"primaryCompletion":4049,"completion":4049,"start":4695,"enrollment":2356,"conditions":4696,"interventions":4697},"NCT02457858","Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study",[87],"2014-08",[18],[4685],{"trials":4699,"activeCount":98},[],{"trials":4701,"activeCount":98},[],{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":98},[],{"intervention":4707,"totalTrials":116,"cells":4708},"Salbutamol 400mcg",{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4723,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4710,"activeCount":98},[],{"trials":4712,"activeCount":98},[4713],{"nctId":4714,"briefTitle":4715,"status":147,"phases":4716,"primaryCompletion":4717,"completion":4717,"start":4718,"enrollment":4719,"conditions":4720,"interventions":4721},"NCT06027606","Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use",[87],"2025-09-25","2023-09-01",81,[4027],[4707,4722],"Budesonide\u002Fformoterol",{"trials":4724,"activeCount":98},[],{"trials":4726,"activeCount":98},[],{"trials":4728,"activeCount":98},[],{"trials":4730,"activeCount":98},[],{"intervention":4722,"totalTrials":116,"cells":4732},{"EARLY_PHASE1":4733,"PHASE1":4735,"PHASE2":4741,"PHASE3":4743,"PHASE4":4745,"NA":4747},{"trials":4734,"activeCount":98},[],{"trials":4736,"activeCount":98},[4737],{"nctId":4714,"briefTitle":4715,"status":147,"phases":4738,"primaryCompletion":4717,"completion":4717,"start":4718,"enrollment":4719,"conditions":4739,"interventions":4740},[87],[4027],[4707,4722],{"trials":4742,"activeCount":98},[],{"trials":4744,"activeCount":98},[],{"trials":4746,"activeCount":98},[],{"trials":4748,"activeCount":98},[],{"intervention":4750,"totalTrials":116,"cells":4751},"Volasertib",{"EARLY_PHASE1":4752,"PHASE1":4754,"PHASE2":4772,"PHASE3":4774,"PHASE4":4776,"NA":4778},{"trials":4753,"activeCount":98},[],{"trials":4755,"activeCount":98},[4756],{"nctId":4757,"briefTitle":4758,"status":1572,"phases":4759,"primaryCompletion":4760,"completion":4761,"start":4762,"enrollment":98,"conditions":4763,"interventions":4769},"NCT02527174","A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia",[87],"2018-05","2018-09","2016-11",[4764,4765,4766,4767,4768],"Leukemia, Myeloid, Acute","Leukemia, Monocytic, Acute","Leukemia, Myelomonocytic, Acute","Leukemia, Erythroblastic, Acute","Leukemia, Megakaryoblastic, Acute",[4750,4770,4771],"Idarubicin","Cytarabine",{"trials":4773,"activeCount":98},[],{"trials":4775,"activeCount":98},[],{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"intervention":4770,"totalTrials":116,"cells":4781},{"EARLY_PHASE1":4782,"PHASE1":4784,"PHASE2":4790,"PHASE3":4792,"PHASE4":4794,"NA":4796},{"trials":4783,"activeCount":98},[],{"trials":4785,"activeCount":98},[4786],{"nctId":4757,"briefTitle":4758,"status":1572,"phases":4787,"primaryCompletion":4760,"completion":4761,"start":4762,"enrollment":98,"conditions":4788,"interventions":4789},[87],[4764,4765,4766,4767,4768],[4750,4770,4771],{"trials":4791,"activeCount":98},[],{"trials":4793,"activeCount":98},[],{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[],{"intervention":4771,"totalTrials":116,"cells":4799},{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4808,"PHASE3":4810,"PHASE4":4812,"NA":4814},{"trials":4801,"activeCount":98},[],{"trials":4803,"activeCount":98},[4804],{"nctId":4757,"briefTitle":4758,"status":1572,"phases":4805,"primaryCompletion":4760,"completion":4761,"start":4762,"enrollment":98,"conditions":4806,"interventions":4807},[87],[4764,4765,4766,4767,4768],[4750,4770,4771],{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[],{"intervention":4817,"totalTrials":116,"cells":4818},"cePolytreg",{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4832,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4820,"activeCount":98},[],{"trials":4822,"activeCount":98},[4823],{"nctId":4824,"briefTitle":4825,"status":1572,"phases":4826,"primaryCompletion":4827,"completion":4827,"start":4828,"enrollment":98,"conditions":4829,"interventions":4831},"NCT05349591","cePolyTregs in Islet Transplantation",[87],"2025-05-22","2022-08-15",[4830],"Diabetes type1",[4817],{"trials":4833,"activeCount":98},[],{"trials":4835,"activeCount":98},[],{"trials":4837,"activeCount":98},[],{"trials":4839,"activeCount":98},[],{"intervention":4841,"totalTrials":116,"cells":4842},"Botox 200 UNT",{"EARLY_PHASE1":4843,"PHASE1":4845,"PHASE2":4865,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4844,"activeCount":98},[],{"trials":4846,"activeCount":98},[4847],{"nctId":4848,"briefTitle":4849,"status":1572,"phases":4850,"primaryCompletion":4851,"completion":4852,"start":4853,"enrollment":98,"conditions":4854,"interventions":4863},"NCT04580238","Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache",[87],"2025-01","2025-06","2023-12",[4855,4856,4857,4858,4859,4860,4861,4862],"Stroke (CVA) or TIA","Headache, Migraine","Botulinum Toxins, Type A","Cerebral Venous Sinus Thrombosis","Carotid Dissection Artery","Vertebral Dissection Artery","Hemorrhagic Stroke","Reversible Cerebral Vasoconstriction Syndrome",[4841,4864],"Non Botox based Standard of Care Treatments for Headache\u002FMigraine",{"trials":4866,"activeCount":98},[],{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"trials":4872,"activeCount":98},[],{"intervention":4864,"totalTrials":116,"cells":4874},{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4883,"PHASE3":4885,"PHASE4":4887,"NA":4889},{"trials":4876,"activeCount":98},[],{"trials":4878,"activeCount":98},[4879],{"nctId":4848,"briefTitle":4849,"status":1572,"phases":4880,"primaryCompletion":4851,"completion":4852,"start":4853,"enrollment":98,"conditions":4881,"interventions":4882},[87],[4855,4856,4857,4858,4859,4860,4861,4862],[4841,4864],{"trials":4884,"activeCount":98},[],{"trials":4886,"activeCount":98},[],{"trials":4888,"activeCount":98},[],{"trials":4890,"activeCount":98},[],{"intervention":4892,"totalTrials":116,"cells":4893},"PolyTregs",{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4906,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4895,"activeCount":98},[],{"trials":4897,"activeCount":98},[4898],{"nctId":4899,"briefTitle":4900,"status":147,"phases":4901,"primaryCompletion":4902,"completion":4903,"start":1692,"enrollment":29,"conditions":4904,"interventions":4905},"NCT03444064","PolyTreg Immunotherapy in Islet Transplantation",[87],"2024-08-12","2024-12-17",[3924,3238],[4892],{"trials":4907,"activeCount":98},[],{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":98},[],{"intervention":4915,"totalTrials":116,"cells":4916},"Antiaging Glycopeptide",{"EARLY_PHASE1":4917,"PHASE1":4919,"PHASE2":4929,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4918,"activeCount":98},[],{"trials":4920,"activeCount":98},[4921],{"nctId":4922,"briefTitle":4923,"status":147,"phases":4924,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":4581,"conditions":4927,"interventions":4928},"NCT03073577","Islet Transplantation Using PKX-001",[87],"2025-05-07","2017-02-17",[966],[4915],{"trials":4930,"activeCount":98},[],{"trials":4932,"activeCount":98},[],{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[],{"intervention":1275,"totalTrials":319,"cells":4938},{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4945,"PHASE4":4959,"NA":4961},{"trials":4940,"activeCount":98},[],{"trials":4942,"activeCount":98},[],{"trials":4944,"activeCount":98},[],{"trials":4946,"activeCount":98},[4947,4951,4955],{"nctId":1266,"briefTitle":1267,"status":147,"phases":4948,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":189,"conditions":4949,"interventions":4950},[88,89],[1272,1273],[1275,1262],{"nctId":2473,"briefTitle":2474,"status":1572,"phases":4952,"primaryCompletion":2476,"completion":2476,"start":2465,"enrollment":98,"conditions":4953,"interventions":4954},[88,89],[2478,1273,2479],[1275,2451],{"nctId":3162,"briefTitle":3163,"status":441,"phases":4956,"primaryCompletion":2476,"completion":2476,"start":2465,"enrollment":16,"conditions":4957,"interventions":4958},[88,89],[3166,1273],[1275,3151],{"trials":4960,"activeCount":98},[],{"trials":4962,"activeCount":98},[4963],{"nctId":4964,"briefTitle":4965,"status":147,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":4968,"enrollment":831,"conditions":4969,"interventions":4971},"NCT03971708","Systemic Effects of Lidocaine Infusion for TAP Block Catheter",[91],"2020-12","2015-06",[4970],"Nephrectomy",[4972,1275],"Lidocaine",{"intervention":1959,"totalTrials":413,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4989},{"trials":4976,"activeCount":98},[],{"trials":4978,"activeCount":98},[],{"trials":4980,"activeCount":98},[],{"trials":4982,"activeCount":98},[],{"trials":4984,"activeCount":98},[4985],{"nctId":1949,"briefTitle":1950,"status":147,"phases":4986,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":9,"conditions":4987,"interventions":4988},[90],[1956,1957],[1936,1959],{"trials":4990,"activeCount":98},[4991,5001],{"nctId":4992,"briefTitle":4993,"status":1572,"phases":4994,"primaryCompletion":4995,"completion":4995,"start":4996,"enrollment":98,"conditions":4997,"interventions":4999},"NCT02463812","Lipid Infusion Following Major Surgery",[91],"2017-04","2015-05",[4998],"Parenteral Nutrition",[5000,1959],"Intralipid",{"nctId":5002,"briefTitle":5003,"status":441,"phases":5004,"primaryCompletion":5005,"completion":5005,"start":5006,"enrollment":5007,"conditions":5008,"interventions":5010},"NCT02050295","Nerve Block Washout",[91],"2018-01","2014-02",31,[5009],"Regional Anesthesia",[1959],{"intervention":3408,"totalTrials":94,"cells":5012},{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5017,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5014,"activeCount":98},[],{"trials":5016,"activeCount":98},[],{"trials":5018,"activeCount":98},[5019],{"nctId":3399,"briefTitle":3400,"status":147,"phases":5020,"primaryCompletion":3402,"completion":3402,"start":3403,"enrollment":628,"conditions":5021,"interventions":5022},[88],[3405,3406],[3408,3390],{"trials":5024,"activeCount":98},[],{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[5029],{"nctId":5030,"briefTitle":5031,"status":147,"phases":5032,"primaryCompletion":5033,"completion":5034,"start":4138,"enrollment":5035,"conditions":5036,"interventions":5038},"NCT02415855","Canadian Pradaxa Acute Stroke Safety Study",[],"2018-03-31","2018-05-18",101,[5037,23],"Ischemic Attack, Transient",[3408],{"intervention":5040,"totalTrials":94,"cells":5041},"propofol",{"EARLY_PHASE1":5042,"PHASE1":5044,"PHASE2":5046,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"trials":5047,"activeCount":98},[5048],{"nctId":5049,"briefTitle":5050,"status":147,"phases":5051,"completion":2214,"start":5052,"enrollment":1290,"conditions":5053,"interventions":5058},"NCT00228267","Propofol Injection for Daily Headache",[88],"2004-09",[5054,5055,5056,5057],"Chronic Headache","Analgesic Rebound Headache","Chronic Daily Headache","Headache, Intractable",[5059],"Propofol",{"trials":5061,"activeCount":98},[],{"trials":5063,"activeCount":98},[],{"trials":5065,"activeCount":98},[5066],{"nctId":5067,"briefTitle":5068,"status":147,"phases":5069,"primaryCompletion":5070,"completion":5070,"start":2056,"enrollment":5071,"conditions":5072,"interventions":5074},"NCT00848861","A Trial Comparing Propofol to Midazolam Plus Meperidine Sedation for Outpatient Colonoscopy",[91],"2006-06",92,[5073],"Sedation",[5040,5075],"midazolam plus meperidine",{"intervention":3229,"totalTrials":94,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5079,"activeCount":98},[],{"trials":5081,"activeCount":98},[],{"trials":5083,"activeCount":98},[5084],{"nctId":3224,"briefTitle":3225,"status":147,"phases":5085,"enrollment":24,"conditions":5086,"interventions":5087},[88],[18],[3215,3229],{"trials":5089,"activeCount":98},[],{"trials":5091,"activeCount":98},[],{"trials":5093,"activeCount":98},[5094],{"nctId":5095,"briefTitle":5096,"status":147,"phases":5097,"primaryCompletion":5098,"completion":2082,"start":1715,"enrollment":1290,"conditions":5099,"interventions":5100},"NCT02847884","IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study",[],"2017-12",[3075,1578],[5101],"Infliximab",{"intervention":5103,"totalTrials":94,"cells":5104},"Ketamine",{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5109,"PHASE3":5111,"PHASE4":5113,"NA":5123},{"trials":5106,"activeCount":98},[],{"trials":5108,"activeCount":98},[],{"trials":5110,"activeCount":98},[],{"trials":5112,"activeCount":98},[],{"trials":5114,"activeCount":98},[5115],{"nctId":5116,"briefTitle":5117,"status":147,"phases":5118,"primaryCompletion":1783,"completion":1783,"start":1715,"enrollment":5119,"conditions":5120,"interventions":5122},"NCT02579642","Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy",[90],48,[5121],"Depressive Disorder",[5103],{"trials":5124,"activeCount":98},[5125],{"nctId":5126,"briefTitle":5127,"status":147,"phases":5128,"primaryCompletion":3497,"completion":3497,"start":2188,"enrollment":5129,"conditions":5130,"interventions":5136},"NCT04701008","Efficacy of Ketamine in Post Anesthesia Recovery Room",[],143,[5131,5132,5133,5134,5135],"Pain, Postoperative","Ketamine Adverse Reaction","Pain, Refractory","Pain, Intractable","Pain, Acute",[5103],{"intervention":4368,"totalTrials":94,"cells":5138},{"EARLY_PHASE1":5139,"PHASE1":5141,"PHASE2":5143,"PHASE3":5149,"PHASE4":5151,"NA":5153},{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[],{"trials":5144,"activeCount":98},[5145],{"nctId":4357,"briefTitle":4358,"status":147,"phases":5146,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":4363,"conditions":5147,"interventions":5148},[88],[4365],[4348,4367,4368,4369,4370],{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[],{"trials":5154,"activeCount":98},[5155],{"nctId":5156,"briefTitle":5157,"status":147,"phases":5158,"primaryCompletion":5159,"completion":5159,"start":5160,"enrollment":831,"conditions":5161,"interventions":5163},"NCT05375916","Comparison of Short-term Sustained-release Opioid in Open Abdominal Urologic Surgeries",[91],"2023-11-30","2022-05-03",[5135,5162],"Opioid Use",[4368],{"intervention":347,"totalTrials":94,"cells":5165},{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5170,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5167,"activeCount":98},[],{"trials":5169,"activeCount":98},[],{"trials":5171,"activeCount":98},[],{"trials":5173,"activeCount":98},[],{"trials":5175,"activeCount":98},[],{"trials":5177,"activeCount":98},[5178,5182],{"nctId":338,"briefTitle":339,"status":147,"phases":5179,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":5180,"interventions":5181},[91],[266,265],[347,268],{"nctId":349,"briefTitle":350,"status":147,"phases":5183,"primaryCompletion":352,"completion":352,"start":353,"enrollment":16,"conditions":5184,"interventions":5185},[91],[266,265],[347,268,268,356,270,271],{"intervention":3649,"totalTrials":94,"cells":5187},{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5192,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5189,"activeCount":98},[],{"trials":5191,"activeCount":98},[],{"trials":5193,"activeCount":98},[5194],{"nctId":3638,"briefTitle":3639,"status":441,"phases":5195,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":413,"conditions":5196,"interventions":5197},[88],[3645,3646],[3629,3648,3649],{"trials":5199,"activeCount":98},[],{"trials":5201,"activeCount":98},[],{"trials":5203,"activeCount":98},[5204],{"nctId":5205,"briefTitle":5206,"status":147,"phases":5207,"primaryCompletion":4852,"completion":4852,"start":2368,"enrollment":2032,"conditions":5208,"interventions":5210},"NCT02965963","The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise",[91],[5209],"Health",[5211,2010,3649],"Dopamine",{"intervention":2010,"totalTrials":94,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5222,"NA":5228},{"trials":5215,"activeCount":98},[],{"trials":5217,"activeCount":98},[],{"trials":5219,"activeCount":98},[],{"trials":5221,"activeCount":98},[],{"trials":5223,"activeCount":98},[5224],{"nctId":2001,"briefTitle":2002,"status":147,"phases":5225,"primaryCompletion":2004,"completion":2004,"start":1159,"enrollment":1981,"conditions":5226,"interventions":5227},[90],[2006,2007,2008],[1988,2010],{"trials":5229,"activeCount":98},[5230],{"nctId":5205,"briefTitle":5206,"status":147,"phases":5231,"primaryCompletion":4852,"completion":4852,"start":2368,"enrollment":2032,"conditions":5232,"interventions":5233},[91],[5209],[5211,2010,3649],{"intervention":5235,"totalTrials":116,"cells":5236},"Propofol and Remifentanil administered by TCI pump",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5243,"PHASE4":5245,"NA":5247},{"trials":5238,"activeCount":98},[],{"trials":5240,"activeCount":98},[],{"trials":5242,"activeCount":98},[],{"trials":5244,"activeCount":98},[],{"trials":5246,"activeCount":98},[],{"trials":5248,"activeCount":98},[5249],{"nctId":5250,"briefTitle":5251,"status":147,"phases":5252,"primaryCompletion":5253,"completion":5253,"start":5254,"enrollment":5035,"conditions":5255,"interventions":5257},"NCT03995134","Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry",[],"2020-01-17","2019-08-03",[5256],"Sedative Adverse Reaction",[5235],{"intervention":5259,"totalTrials":116,"cells":5260},"TDF\u002FFTC\u002FLPV\u002Fr",{"EARLY_PHASE1":5261,"PHASE1":5263,"PHASE2":5265,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5262,"activeCount":98},[],{"trials":5264,"activeCount":98},[],{"trials":5266,"activeCount":98},[],{"trials":5268,"activeCount":98},[],{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[5273],{"nctId":5274,"briefTitle":5275,"status":441,"phases":5276,"primaryCompletion":2980,"completion":3522,"start":3922,"enrollment":19,"conditions":5277,"interventions":5278},"NCT01614405","Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis",[91],[2934],[5259],{"intervention":5000,"totalTrials":116,"cells":5280},{"EARLY_PHASE1":5281,"PHASE1":5283,"PHASE2":5285,"PHASE3":5287,"PHASE4":5289,"NA":5291},{"trials":5282,"activeCount":98},[],{"trials":5284,"activeCount":98},[],{"trials":5286,"activeCount":98},[],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[5293],{"nctId":4992,"briefTitle":4993,"status":1572,"phases":5294,"primaryCompletion":4995,"completion":4995,"start":4996,"enrollment":98,"conditions":5295,"interventions":5296},[91],[4998],[5000,1959],{"intervention":5298,"totalTrials":116,"cells":5299},"L-Arginine",{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5304,"PHASE3":5306,"PHASE4":5308,"NA":5310},{"trials":5301,"activeCount":98},[],{"trials":5303,"activeCount":98},[],{"trials":5305,"activeCount":98},[],{"trials":5307,"activeCount":98},[],{"trials":5309,"activeCount":98},[],{"trials":5311,"activeCount":98},[5312],{"nctId":5313,"briefTitle":5314,"status":147,"phases":5315,"primaryCompletion":4537,"completion":5316,"start":444,"enrollment":19,"conditions":5317,"interventions":5319},"NCT00718510","L-arginine in Treatment as Usual in Schizophrenia",[91],"2012-10",[5318],"Schizophrenia",[5298],{"intervention":5321,"totalTrials":116,"cells":5322},"Vitamin D",{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5327,"PHASE3":5329,"PHASE4":5331,"NA":5333},{"trials":5324,"activeCount":98},[],{"trials":5326,"activeCount":98},[],{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[],{"trials":5332,"activeCount":98},[],{"trials":5334,"activeCount":98},[5335],{"nctId":5336,"briefTitle":5337,"status":1572,"phases":5338,"enrollment":98,"conditions":5339,"interventions":5341},"NCT01609439","Preoperative Vitamin D for Post-thyroidectomy Hypocalcemia",[91],[5340],"Hypocalcemia",[5321],{"intervention":5075,"totalTrials":116,"cells":5343},{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5350,"PHASE4":5352,"NA":5354},{"trials":5345,"activeCount":98},[],{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[],{"trials":5353,"activeCount":98},[],{"trials":5355,"activeCount":98},[5356],{"nctId":5067,"briefTitle":5068,"status":147,"phases":5357,"primaryCompletion":5070,"completion":5070,"start":2056,"enrollment":5071,"conditions":5358,"interventions":5359},[91],[5073],[5040,5075],{"intervention":5361,"totalTrials":116,"cells":5362},"0.5% Ropivacaine\u002F0.125% Bupivacaine local anesthetic mixture",{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5369,"PHASE4":5371,"NA":5373},{"trials":5364,"activeCount":98},[],{"trials":5366,"activeCount":98},[],{"trials":5368,"activeCount":98},[],{"trials":5370,"activeCount":98},[],{"trials":5372,"activeCount":98},[],{"trials":5374,"activeCount":98},[5375],{"nctId":5376,"briefTitle":5377,"status":441,"phases":5378,"primaryCompletion":4602,"completion":4602,"start":4968,"enrollment":5379,"conditions":5380,"interventions":5382},"NCT02450045","Pre-op Femoral Nerve Block for Hip Fracture",[91],73,[5381],"Hip Fractures",[5361],{"intervention":5384,"totalTrials":116,"cells":5385},"Antihypertensive medication",{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"trials":5393,"activeCount":98},[],{"trials":5395,"activeCount":98},[],{"trials":5397,"activeCount":98},[5398],{"nctId":5399,"briefTitle":5400,"status":147,"phases":5401,"primaryCompletion":5402,"completion":5402,"start":5403,"enrollment":5404,"conditions":5405,"interventions":5407},"NCT05047731","Antihypertensive Deprescribing in Long-term Care",[91],"2025-11-30","2021-09-20",522,[31,5406],"Frailty",[5384],{"intervention":5409,"totalTrials":116,"cells":5410},"Apixaban",{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5412,"activeCount":98},[],{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[],{"trials":5418,"activeCount":98},[],{"trials":5420,"activeCount":98},[],{"trials":5422,"activeCount":98},[5423],{"nctId":5424,"briefTitle":5425,"status":147,"phases":5426,"primaryCompletion":5427,"completion":5427,"start":5428,"enrollment":312,"conditions":5429,"interventions":5430},"NCT04435418","Eliquis Acute Stroke Safety Evaluation",[],"2019-09-09","2017-03-01",[1743,3405,1615],[5409],{"intervention":4972,"totalTrials":116,"cells":5432},{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5439,"PHASE4":5441,"NA":5443},{"trials":5434,"activeCount":98},[],{"trials":5436,"activeCount":98},[],{"trials":5438,"activeCount":98},[],{"trials":5440,"activeCount":98},[],{"trials":5442,"activeCount":98},[],{"trials":5444,"activeCount":98},[5445],{"nctId":4964,"briefTitle":4965,"status":147,"phases":5446,"primaryCompletion":4967,"completion":4967,"start":4968,"enrollment":831,"conditions":5447,"interventions":5448},[91],[4970],[4972,1275],{"intervention":5450,"totalTrials":116,"cells":5451},"General anesthetic",{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5456,"PHASE3":5458,"PHASE4":5460,"NA":5462},{"trials":5453,"activeCount":98},[],{"trials":5455,"activeCount":98},[],{"trials":5457,"activeCount":98},[],{"trials":5459,"activeCount":98},[],{"trials":5461,"activeCount":98},[],{"trials":5463,"activeCount":98},[5464],{"nctId":5465,"briefTitle":5466,"status":147,"phases":5467,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":5119,"conditions":5470,"interventions":5472},"NCT03471442","Erector Spinae Plane Block Versus Paravertebral Block",[91],"2021-04-27","2018-05-29",[21,5131,5471],"Anesthesia, Local",[5450,5473,5474],"Opioids","Anesthetics, Local",{"intervention":5473,"totalTrials":116,"cells":5476},{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5481,"PHASE3":5483,"PHASE4":5485,"NA":5487},{"trials":5478,"activeCount":98},[],{"trials":5480,"activeCount":98},[],{"trials":5482,"activeCount":98},[],{"trials":5484,"activeCount":98},[],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[5489],{"nctId":5465,"briefTitle":5466,"status":147,"phases":5490,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":5119,"conditions":5491,"interventions":5492},[91],[21,5131,5471],[5450,5473,5474],{"intervention":5474,"totalTrials":116,"cells":5494},{"EARLY_PHASE1":5495,"PHASE1":5497,"PHASE2":5499,"PHASE3":5501,"PHASE4":5503,"NA":5505},{"trials":5496,"activeCount":98},[],{"trials":5498,"activeCount":98},[],{"trials":5500,"activeCount":98},[],{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[5507],{"nctId":5465,"briefTitle":5466,"status":147,"phases":5508,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":5119,"conditions":5509,"interventions":5510},[91],[21,5131,5471],[5450,5473,5474],{"intervention":5512,"totalTrials":116,"cells":5513},"Influenza vaccine: Vaxigrip or Fluviral and Intanza",{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5520,"PHASE4":5522,"NA":5524},{"trials":5515,"activeCount":98},[],{"trials":5517,"activeCount":98},[],{"trials":5519,"activeCount":98},[],{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[],{"trials":5525,"activeCount":98},[5526],{"nctId":5527,"briefTitle":5528,"status":147,"phases":5529,"primaryCompletion":1594,"completion":2632,"start":5530,"enrollment":5531,"conditions":5532,"interventions":5534},"NCT01180699","Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients",[91],"2010-10",229,[5533],"Influenza Vaccine",[5512],{"intervention":5536,"totalTrials":116,"cells":5537},"Docusate Sodium, Sennoside",{"EARLY_PHASE1":5538,"PHASE1":5540,"PHASE2":5542,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5539,"activeCount":98},[],{"trials":5541,"activeCount":98},[],{"trials":5543,"activeCount":98},[],{"trials":5545,"activeCount":98},[],{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":98},[5550],{"nctId":5551,"briefTitle":5552,"status":147,"phases":5553,"primaryCompletion":5530,"completion":5530,"start":3005,"enrollment":2329,"conditions":5554,"interventions":5557},"NCT00902031","Effectiveness of Docusate in Preventing\u002FTreating Constipation in Palliative Care Patients",[91],[5555,5556],"Constipation","Palliative Care",[5536,5558],"Sennoside + Placebo",{"intervention":5558,"totalTrials":116,"cells":5560},{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5565,"PHASE3":5567,"PHASE4":5569,"NA":5571},{"trials":5562,"activeCount":98},[],{"trials":5564,"activeCount":98},[],{"trials":5566,"activeCount":98},[],{"trials":5568,"activeCount":98},[],{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[5573],{"nctId":5551,"briefTitle":5552,"status":147,"phases":5574,"primaryCompletion":5530,"completion":5530,"start":3005,"enrollment":2329,"conditions":5575,"interventions":5576},[91],[5555,5556],[5536,5558],{"intervention":5578,"totalTrials":116,"cells":5579},"Vaxigrip",{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5581,"activeCount":98},[],{"trials":5583,"activeCount":98},[],{"trials":5585,"activeCount":98},[],{"trials":5587,"activeCount":98},[],{"trials":5589,"activeCount":98},[],{"trials":5591,"activeCount":98},[5592],{"nctId":5593,"briefTitle":5594,"status":147,"phases":5595,"primaryCompletion":4580,"completion":5596,"start":4538,"enrollment":5597,"conditions":5598,"interventions":5600},"NCT00760175","Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients",[91],"2010-02",85,[5599,5533],"Influenza Virus",[5578],{"intervention":5602,"totalTrials":116,"cells":5603},"Insulin glargine",{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5610,"PHASE4":5612,"NA":5614},{"trials":5605,"activeCount":98},[],{"trials":5607,"activeCount":98},[],{"trials":5609,"activeCount":98},[],{"trials":5611,"activeCount":98},[],{"trials":5613,"activeCount":98},[],{"trials":5615,"activeCount":98},[5616],{"nctId":5617,"briefTitle":5618,"status":147,"phases":5619,"primaryCompletion":5316,"completion":5316,"start":2631,"enrollment":312,"conditions":5620,"interventions":5622},"NCT01335763","Pharmacist Intervention for Glycemic Control in The Community",[91],[5621],"Type 2 Diabetes",[5602],{"intervention":5211,"totalTrials":116,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5626,"activeCount":98},[],{"trials":5628,"activeCount":98},[],{"trials":5630,"activeCount":98},[],{"trials":5632,"activeCount":98},[],{"trials":5634,"activeCount":98},[],{"trials":5636,"activeCount":98},[5637],{"nctId":5205,"briefTitle":5206,"status":147,"phases":5638,"primaryCompletion":4852,"completion":4852,"start":2368,"enrollment":2032,"conditions":5639,"interventions":5640},[91],[5209],[5211,2010,3649],{"intervention":5642,"totalTrials":116,"cells":5643},"Pregabalin",{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5650,"PHASE4":5652,"NA":5654},{"trials":5645,"activeCount":98},[],{"trials":5647,"activeCount":98},[],{"trials":5649,"activeCount":98},[],{"trials":5651,"activeCount":98},[],{"trials":5653,"activeCount":98},[],{"trials":5655,"activeCount":98},[5656],{"nctId":5657,"briefTitle":5658,"status":441,"phases":5659,"primaryCompletion":5660,"completion":5660,"start":2907,"enrollment":413,"conditions":5661,"interventions":5663},"NCT00787462","Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy",[91],"2013-02",[5662],"Small-Fiber Neuropathy",[5642],{"intervention":5665,"totalTrials":116,"cells":5666},"Regional citrate anticoagulation",{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5673,"PHASE4":5675,"NA":5677},{"trials":5668,"activeCount":98},[],{"trials":5670,"activeCount":98},[],{"trials":5672,"activeCount":98},[],{"trials":5674,"activeCount":98},[],{"trials":5676,"activeCount":98},[],{"trials":5678,"activeCount":98},[5679],{"nctId":5680,"briefTitle":5681,"status":147,"phases":5682,"primaryCompletion":5683,"completion":5683,"start":5684,"enrollment":152,"conditions":5685,"interventions":5687},"NCT00583765","Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration",[],"2008-03","2005-04",[5686],"Kidney Failure, Acute",[5665],{"intervention":356,"totalTrials":116,"cells":5689},{"EARLY_PHASE1":5690,"PHASE1":5692,"PHASE2":5694,"PHASE3":5696,"PHASE4":5698,"NA":5700},{"trials":5691,"activeCount":98},[],{"trials":5693,"activeCount":98},[],{"trials":5695,"activeCount":98},[],{"trials":5697,"activeCount":98},[],{"trials":5699,"activeCount":98},[],{"trials":5701,"activeCount":98},[5702],{"nctId":349,"briefTitle":350,"status":147,"phases":5703,"primaryCompletion":352,"completion":352,"start":353,"enrollment":16,"conditions":5704,"interventions":5705},[91],[266,265],[347,268,268,356,270,271],{"intervention":5707,"totalTrials":116,"cells":5708},"Patient controlled opioid analgesia",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":98},[],{"trials":5712,"activeCount":98},[],{"trials":5714,"activeCount":98},[],{"trials":5716,"activeCount":98},[],{"trials":5718,"activeCount":98},[],{"trials":5720,"activeCount":98},[5721],{"nctId":5722,"briefTitle":5723,"status":147,"phases":5724,"primaryCompletion":5725,"completion":5725,"start":5726,"enrollment":2032,"conditions":5727,"interventions":5732},"NCT03458598","Pre-Operative Single Shot Rectus Sheath Block",[91],"2019-02-05","2018-02-16",[5728,5729,5730,5731,5162,5471,5131],"Bladder Neoplasm","Prostate Neoplasm","Pelvic Neoplasm","Urologic Neoplasms",[5707],{"intervention":5734,"totalTrials":116,"cells":5735},"intravenous saline hydration + mannitol + furosemide",{"EARLY_PHASE1":5736,"PHASE1":5738,"PHASE2":5740,"PHASE3":5742,"PHASE4":5744,"NA":5746},{"trials":5737,"activeCount":98},[],{"trials":5739,"activeCount":98},[],{"trials":5741,"activeCount":98},[],{"trials":5743,"activeCount":98},[],{"trials":5745,"activeCount":98},[],{"trials":5747,"activeCount":98},[5748],{"nctId":5749,"briefTitle":5750,"status":147,"phases":5751,"primaryCompletion":5752,"start":5753,"enrollment":721,"conditions":5754,"interventions":5757},"NCT00175227","Prevention of Contrast-Induced Nephropathy",[91],"2000-10","1996-05",[5755,447,5756],"Contrast-induced Nephropathy","Chronic Renal Failure",[5734,5758],"intravenous saline hydration",{"intervention":5758,"totalTrials":116,"cells":5760},{"EARLY_PHASE1":5761,"PHASE1":5763,"PHASE2":5765,"PHASE3":5767,"PHASE4":5769,"NA":5771},{"trials":5762,"activeCount":98},[],{"trials":5764,"activeCount":98},[],{"trials":5766,"activeCount":98},[],{"trials":5768,"activeCount":98},[],{"trials":5770,"activeCount":98},[],{"trials":5772,"activeCount":98},[5773],{"nctId":5749,"briefTitle":5750,"status":147,"phases":5774,"primaryCompletion":5752,"start":5753,"enrollment":721,"conditions":5775,"interventions":5776},[91],[5755,447,5756],[5734,5758],{"intervention":5778,"totalTrials":116,"cells":5779},"Azithromycin",{"EARLY_PHASE1":5780,"PHASE1":5782,"PHASE2":5784,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5781,"activeCount":98},[],{"trials":5783,"activeCount":98},[],{"trials":5785,"activeCount":98},[],{"trials":5787,"activeCount":98},[],{"trials":5789,"activeCount":98},[],{"trials":5791,"activeCount":98},[5792],{"nctId":5793,"briefTitle":5794,"status":147,"phases":5795,"primaryCompletion":4537,"completion":4537,"start":5796,"enrollment":263,"conditions":5797,"interventions":5799},"NCT01154569","Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)",[91],"2010-06",[5798],"Bariatric Surgery",[5778],{"intervention":5801,"totalTrials":116,"cells":5802},"Lidocaine hydrochloride (HCl) 1% solution",{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5807,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5804,"activeCount":98},[],{"trials":5806,"activeCount":98},[],{"trials":5808,"activeCount":98},[],{"trials":5810,"activeCount":98},[],{"trials":5812,"activeCount":98},[],{"trials":5814,"activeCount":98},[5815],{"nctId":5816,"briefTitle":5817,"status":147,"phases":5818,"primaryCompletion":5819,"completion":5819,"start":5820,"enrollment":5821,"conditions":5822,"interventions":5823},"NCT01814657","Optimizing Patient Analgesic Experience During IVF",[91],"2015-11-07","2013-03",308,[2610],[5801,5824],"Sterile Normal Saline%",{"intervention":5824,"totalTrials":116,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5831,"PHASE3":5833,"PHASE4":5835,"NA":5837},{"trials":5828,"activeCount":98},[],{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":98},[],{"trials":5834,"activeCount":98},[],{"trials":5836,"activeCount":98},[],{"trials":5838,"activeCount":98},[5839],{"nctId":5816,"briefTitle":5817,"status":147,"phases":5840,"primaryCompletion":5819,"completion":5819,"start":5820,"enrollment":5821,"conditions":5841,"interventions":5842},[91],[2610],[5801,5824],{"intervention":5844,"totalTrials":116,"cells":5845},"1.5% diclofenac in 45.5% DMSO",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5850,"PHASE3":5852,"PHASE4":5854,"NA":5856},{"trials":5847,"activeCount":98},[],{"trials":5849,"activeCount":98},[],{"trials":5851,"activeCount":98},[],{"trials":5853,"activeCount":98},[],{"trials":5855,"activeCount":98},[],{"trials":5857,"activeCount":98},[5858],{"nctId":5859,"briefTitle":5860,"status":147,"phases":5861,"completion":2930,"start":1129,"enrollment":1290,"conditions":5862,"interventions":5864},"NCT00471393","Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease",[91],[5863],"Temporomandibular Degenerative Joint Disease",[5844,5865],"45.5% DMSO",{"intervention":5865,"totalTrials":116,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5874,"PHASE4":5876,"NA":5878},{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[],{"trials":5873,"activeCount":98},[],{"trials":5875,"activeCount":98},[],{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[5880],{"nctId":5859,"briefTitle":5860,"status":147,"phases":5881,"completion":2930,"start":1129,"enrollment":1290,"conditions":5882,"interventions":5883},[91],[5863],[5844,5865],{"intervention":1295,"totalTrials":116,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5890,"PHASE3":5892,"PHASE4":5894,"NA":5896},{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[],{"trials":5891,"activeCount":98},[],{"trials":5893,"activeCount":98},[],{"trials":5895,"activeCount":98},[],{"trials":5897,"activeCount":98},[5898],{"nctId":1285,"briefTitle":1286,"status":147,"phases":5899,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":5900,"interventions":5901},[91],[1292,1293],[1295,449],{"intervention":5903,"totalTrials":116,"cells":5904},"Mannitol",{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5911,"PHASE4":5913,"NA":5915},{"trials":5906,"activeCount":98},[],{"trials":5908,"activeCount":98},[],{"trials":5910,"activeCount":98},[],{"trials":5912,"activeCount":98},[],{"trials":5914,"activeCount":98},[],{"trials":5916,"activeCount":98},[5917],{"nctId":5918,"briefTitle":5919,"status":147,"phases":5920,"primaryCompletion":4967,"completion":4967,"start":2255,"enrollment":1081,"conditions":5921,"interventions":5922},"NCT02630511","Asthma Exacerbations and Vascular Function",[91],[1718],[5903,5923],"Methacholine",{"intervention":5923,"totalTrials":116,"cells":5925},{"EARLY_PHASE1":5926,"PHASE1":5928,"PHASE2":5930,"PHASE3":5932,"PHASE4":5934,"NA":5936},{"trials":5927,"activeCount":98},[],{"trials":5929,"activeCount":98},[],{"trials":5931,"activeCount":98},[],{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[5938],{"nctId":5918,"briefTitle":5919,"status":147,"phases":5939,"primaryCompletion":4967,"completion":4967,"start":2255,"enrollment":1081,"conditions":5940,"interventions":5941},[91],[1718],[5903,5923]]